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CHAPTER I 
ORAL MUCOSA DRUG DELIVERY SYSTEM 
 
   Oral routes of drug administration have wide acceptance up to 50-60 % 
of total dosage forms. Solid dosage forms are popular because of ease of 
administration, acute dosage, self-medication, pain avoidance and most 
importantly the patient compliance. 
The most popular solid dosage forms are being tablets and capsules; 
one important drawback of this dosage forms for some patients, is the difficult 
to swallow. Drinking water plays an important role in the swallowing of oral 
dosage forms. Often times people experience inconvenience in swallowing 
conventional dosage forms such as tablet when water is not available, in the 
case of the motion sickness (kinetosis) and sudden episodes of coughing 
during the common cold, allergic condition and bronchitis. For these reason, 
tablets that can rapidly dissolve or disintegrate in the oral cavity have attracted 
a great deal of attention, or dispersible tablets are not indicated for people who 
have swallowing difficulties, but also are ideal for active people. 
Fast dissolving tablets are also called as mouth-dissolving tablets; melt 
in mouth tablets, orodispersible tablets, rapimelts, porous tablets,quick 
dissolving etc., (DebjitBhowmik, Chiranjib. Et., 2009).  
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The oral mucosa is composed of an outermost layer of stratified 
squamous epithelium. Below this lies a basement membrane, a lamina propria 
followed by the submucosa as the innermost layer. The epithelium is similar to 
stratified squamous epithelia found in the rest of the body in that it has 
mitotically active basal cell layer, advancing through a number of differentiating 
intermediate layers to the superficial layes, where cells are shed from the 
surface of the epithelium. The epithelium of the buccal mucosa is about 40-50 
cell layers thick, while that of the sublingual epithelium contains somewhat 
fewer. The epithelium cells increase in size and Become flatter                as they 
travel from the basal layers to the superficial layers (Amir. H Shajaeietal., 1998).  
The turnover time for the buccal epithelium has been estimated at 5-6 
days, and this is probably representative of the oral mucosa as a whole. The 
oral mucosal thickness varies depending on the site: the buccal mucosa 
measures at 500-800µm, while the mucosal thickness of the hard and soft 
palates, the floor of the mouth, the ventral tongue, and the gingivae  measure 
at about 100-200 µm. The composition of the epithelium also varies depending 
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on the site in the oral cavity. The mucosae of areas subject to mechanical stress 
(The gingivae and hard palate) are keratinized similar to the epidermis. The 
mucosae of the soft palate, the sublingual, and the buccal regions, however, 
are not keratinized. The keratinized epithelia contain neutral lipids like 
ceramides and acylceramides which have been associated with the barrier 
function. These epithelia are relatively impermeable to water. In contrast , non-
keratinized epithelia, such as the floor of the mouth and the buccal epithelia do 
not contain acylceramides and only have small amounts of ceramide. They also 
contain small amounts of neutral but polar lipids, mainly cholesterol sulfate and 
glucosylceramides. These epithelia have been found to be considerably more 
permeable to water than keratinized epithelia.  
 
Saliva is an aqueous fluid with 1% organic and inorganic materials. The 
major determinant of the salivary composition is the flow rate which in turn 
depends upon three factors: The time of day, the type of stimulus, and the 
degree of stimulation. The salivary PH ranges from 5.5 to 7 depending on the 
flow rate. At high flow rates, the sodium and bicarbonate concentrations 
increase leading to an increase in the PH. The daily salivary volume is between 
0.5 to 2 litters and it is this amount of fluid that is available to hydrate oral 
mucosal dosage forms. A main reason behind the selection of hydrophilic 
polymeric matrices as vehicles for oral trans mucosal drug delivery systems is 
this water rich environment of the oral cavity ( Amir H.shojaei et al.,1998).  
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ORAL DISSOLVING TABLETS 
Oral dissolving tablets defined as a solid dosage form conflict nearly 35% 
of the general population. To solve the above mentioned problem, 
pharmaceutical technologists have put in their best efforts to develop a fast 
dissolving drug delivery i.e. Fast dissolving tablet that disintegrates and 
dissolves dissolves rapidly in the saliva, within a few seconds without the need 
of drinking water or chewing.  A Fast dissolving tablet usually dissolves in the 
oral cavity within 15 seconds to 3 minutes. Most of FDTS include certain super 
disintegrants and taste masking agents. Fast dissolving tablets have formulated 
for paediatric, geriatric, and bedridden patients (Arijit Gandhi et al, and Errolla 
Mahesh et al.,2012). 
Fast dissolving tablets are those when put on tongue disintegrate 
instaneously releasing the drug which dissolve or disperses in the saliva. Some 
drugs are absorbed from the mouth, pharynx and oesophagus as the saliva 
passes down into the stomach. In such cases, bioavailability of drug is 
signicantly greater than those observed from conventional tablets dosage form. 
Their growing importance was underlined recently when European 
pharmacopoeia adopted the term “orodispersibles tablet “as a tablet that to be 
placed in the mouth where it disperse rapidly before swallowing. The 
bioavailability of some drugs maybe increased due to absorption of drug in oral 
cavity and also due to pregastric absorption of saliva containing dispersed 
drugs that pass down into the stomach (Mohit Mangalet al., 2012). 
CHAPTER I                                                                            INTRODUCTION 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 5 
 
 
CRITERIA FOR ORAL DISSOLVING DRUG DELVERY 
• Not require water to swallow and should dissolve or disintegrate in the 
mouth within a few seconds.  
• Allow high drug loading. Be compatible with taste masking and other 
excipients.  
• Have sufficient strength to withstand the rigors of the manufacturing 
process and post manufacturing handling.  
• Exhibit low sensitivity to environmental conditions such as humidity and 
temperature.  
• Be adaptable and amenable to exciting processing and packaging 
machinery.  
• Rapid dissolution and absorption of drug, which may produce rapid onset 
of action.  
• Be portable without fragility concern.  
• Have a pleasing mouth feel.  
• Leave minimal or no patients who refuse to swallow a tablet, such a 
paediatric and geriatric patientsand psychiatric patients.  
• Convenience of administration and accurate dosing as compared to 
liquid.  
• Allow the manufacture of tablets using conventional processing and 
packaging equipment’s at low cost (DebiitBhowmik et al., 2009 and 
Sharma Deepak et al ., 2012). 
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ADVANTAGES:  
• Ease of administration to patients who cannot swallow, such as the 
elderly, stroke victims and bed ridden patients. 
• Patient’s ompliance for disabled bed ridden patients and for travelling 
and busy people who do not have ready access to water. 
• Good mouth feel property of Mouth dissolving drug delivery system helps 
to change the basic view of medication drugs.  
• Convenience of administration and accurate dosing as compared to 
liquid formulations.  
• Benefit of liquid medication in the form of solid preparation.  
• More rapid drug absorption from the pregastric area i.e. mouth, pharynx 
and oesophagus which may produce rapid onset of action.  
• Pre-gastric absorption can result in improved bio-availability, reduced 
dose and improved clinical performance by reducing side effects.  
• New business opportunity produced differentiation, line extension and 
lifecycle management, exclusivity of product promotion and patent-life 
extension.  
• The risk of chocking or suffocation during oral administration of 
conventional formulation due to physical obstruction is avoided, thus 
providing improved safety.  
• Beneficial in cases such as motion sickness (kinetosis).sudden episodes 
of allergic attack or coughing, where an ultra- rapid onset of action 
required (Arijit Gandhi et al.,2012).  
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LIMITATIONS OF MOUTH DISSOLVING TABLETS:  
• The tablets may leave unpleasant taste and/or grittiness in mouth if not 
formulated properly.  
• The tablets usually have insufficient mechanical strength. Hence, careful 
handling is required.  
 
DRUG SELECTION CRITERIA:  
• The ideal characteristics of a drug for Mouth Dissolving tablet include.  
• Ability to permeate the oral mucosa. 
• At least partially non-ionized at the oral cavity pH. 
• Have the ability to diffuse and partition into the epithelium of the upper  GIT.  
• Small to moderate molecular weight. 
• Low dose drug preferably less than 50 mg.  
• Short half life and frequent dosing drugs are unsuitable for MDT.  
• Very bitter or unacceptable taste and odor drug are unsuitable for MDT.  
• The role of excipients is important in the formulation of mouth dissolving 
tablets.  
• These inactive food grade ingredients, when incorporated in the formulation, 
impart the desired organoleptic properties and product efficacy. Excipients 
are general and can be used for a broad range of actives, except some 
actives that require masking agents. Binders keep the composition of these 
mouth dissolving tablets together during the compression stage.  
• Important ingredients that are used in the formulation of MDTs should 
allow quick release of the drug, resulting in faster dissolution. This 
includes both the actives and the excipients.  
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• Disintegration and solubilisation of a directly compressed tablet depend 
on single or combined effects of disintegrants, water soluble excipients 
and effervescent agents (Mayuri et al., 2014, and Md. Neha Siddiqui et 
al ., 2010).  
 
TECHNOLOGIES USED FOR MANUFACTURING OF MDTS 
1. LYOPHILIZATION OR FREEZE DRYING.  
A process in which water is sublimated from the product after freezing. 
Lypohilization is a pharmaceutical technology which allows drying of heat 
sensitive drugs and biological at low temperature under conditions that allow 
removal of water sublimation. Lyphilization process imparts glossy amorphous 
structure to the bulking agent and sometimes to drug, there by enhancing the 
dissolution characteristics of the formulation (Bhasin et al.,2011,Bandari et 
al.,2008 and pahwa et al., 2010).  
2. MOLDING.  
In this method, molded tablets are prepared by using water soluble 
ingredients so that the tablets dissolve completely and rapidly .  
The powder blend is moistened with a hydro alcoholic solvent and is molded 
into tablets under pressure lower than that used in conventional tablet 
compression. The solvent is then  removed by air drying . Molded tablets are 
very less compact than compressed tablets .These posses porous structure 
that enhances dissolution (Asish et al., 2011, Bandari et al., and Pahwa                 
et al.,2010) 
3. COTTON CANDY PROCESS: 
This process is named as it utilize a unique spinning mechanism to 
produce floss like crystalline structure, which mimic cotton candy. Cotton candy 
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process involves formation of matrix of polysaccharides or saccharides by 
simultaneous action of flash melting and spinning. 
The matrix formed is partially recrystallized to have improved flow 
properties and compressibility. This candy floss matrix is then milled and 
blended with active ingredients and excipients and subsequently compressed 
to MDTs (Alok Kumar Gupta et al., 2011, and Shukla et al., 2009).  
4. SPRAY DRYING 
Spray drying can produce highly porous and fine powders that dissolve 
rapidly. The formulations are incorporated by hydrolysed gelatins as supporting 
agents, mannitol as bulking agents, sodium carboxymethel cellulose or 
crosscarmellose sodium as disintegrating and in acidic material (e.g. citric acid) 
and or alkali material (e.g. Sodium bicarbonate)to enhance disintegration and 
dissolution. Tablet compressed from the spray dried powder disintegrated 
within 20 seconds when immersed in an aqueous medium (Rakesh Kumar 
Bhasin et al., 2011 and Siraj sheikh et al., 2010). 
 
5. MASS EXTRUSION  
This technology involves softening the active blend using the solvent 
mixture of water soluble poly ethylene glycol, using methanol and expulsion of 
softened mass through the extruder or syringe to get a cylinder of the product 
into even segments using heated blade to form tablets. The dried cylinder can 
also be used to coat granules of bitter tasting drugs and thereby masking their 
bitter taste (Pooja Mathur et al., 2010).  
6. SUBLIMATION. 
The slow dissolution of the compressed tablet containing even highly water 
soluble ingredients is due to the low porosity of the tablets. Inert solid 
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ingredients that volatilize readily (e.g. Urea, ammonium bicarbonate, hexa 
methylene tetramine, camphor etc ) were added to the other tablet ingredients 
and the mixture is compressed into tablets. The volatile materials were then 
removed via sublimation, which generates porous structure additionally, 
several solvents (e.g. cyclohexane, benzene) can be also used as pore forming 
agents (Ashish.P et al.,2011, bandari et al., 2008 and kumar et al.,2012). 
7. NANONIZATION
A recently developed nanomelt technology involves reduction in the 
particle size of drug to nanosize by wet milling technique. The namocrystals of 
the drug are stabilized against agglomeration by surface adsorption on selected 
stabilisers, which are then incorporated into MDTs. This technique is mainly 
advantageous for poor water soluble drugs and also for a wide range of does 
(to 200mg of drug per unit) (Gupta. A et.al., 2010 and Kamal Saroha 
et.al.,2010). 
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8. DIRECT COMPRESSION 
 Direct compression method is the easiest way to manufacture tablets. 
Conventional equipment, commonly available excipients and a limited number 
of processing steps are involved in direct compression. Also high doses can be 
accommodated and final weight of tablet can easily exceed that of other 
production method. Directly compressed tablet’s disintegration and 
solubilization depends on  single or combined action of disintegrates, water 
soluble excipients and effervescent agent (Deepak Bhowmik et al., 2009, 
Kumar et al., 2012 and Bhasin et al., 2011). 
A. Superdisintegrants: in many orally disintegrating tablet technologies 
based on direct compression, the addition of superdisintegrants 
principally affects the rate of disintegration and hence the dissolution. The 
presence of other formulation ingredients such as water-soluble 
excipients and effervescent agents further has tents the process of 
disintegration. 
B. Sugar based Excipients: the use of sugar based excipients especially 
bulking agents like dextrose, fructose, is omalt, lactilo, maltilol, maltose, 
mannitol, sorbitol, starch hydrolysate, polydextrose and xylitol, which 
display water soluble and pleasing mouth feel. 
PATENTED TECHNOLOGIES FOR FAST DISSOLVING TABLETS 
1. Zydis Technology 
2. Orasolv Technology 
3. Durasolv Technology 
4. Flash dose Technology 
5. Shear form Technology 
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6. Wow tab Technology 
7. Flash tab Technology 
8. Dispersible tablet Technology 
9. Frosta Technology 
10. Pharm burst Technology 
11. Oraquick Technology 
12. Quick dis Technology 
13. Nano crystal Technology 
14. Ziplets/ Advatab Technology 
15. Ceform Technology 
16. Quicksolv Technology 
17. Lyo Technology 
 
1. Zydis technology 
Zydis is the first mouth dissolving dosage form in the market. Zydis 
matrix is made up of a number of ingredients in order to obtain different 
objectives. Polymers such as gelatin dextran or alginates are added to impart 
strength during handling. This form a glossy and amorphous structure. This 
technology involves softening the active blend using the solvent mixture of 
water soluble poly ethylene glycol using methanol and expulsion of softened 
mass through the extruder or syringe to get a cylinder of the product into even 
segments using heated blade to form tablets. The dried cylinder can also be 
used to coat granules of bitter tasting drugs and thereby masking their bitter 
taste (Tejvirkaruret.al., 2011). 
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Drawback: 
A. Water insoluble drug can be incorporated only up to 400mg per tablet or 
less. 
B. Fragility and poor stability. 
2. OROSOLV TECHNOLOGY. 
Orosolv technology has been developed by “CIMA” tabs. In this system 
active medicament is taste masked. It also contains effervescent disintegrating 
agent. Tables are made by direct compression technique at low compression 
force in order to minimize oral dissolution time. Conventional blenders and 
tablet machine is used to produce the tablets. The tablets produced are soft 
and friable and packaged in specially designed pick and place system 
(Srivastava saurabh et al., 2012 and Nishtha Tiwari et al., 2012). 
3. Durssolv Technology. 
Durosolv is the patented technology of “Cima” labs. The tablets madeby 
this technology consist of a drug, fillers and lubricant. Tablets are prepared by 
using conventional tableting equipment and have good rigidity. These can be 
packed into conventional packaging system like blisters. Durisolv is an 
appropriate technology for products requiring low amounts of active ingredients 
(Ashish. P.et al., 2011 and RajashreePanigrahi et al., 2010). 
4.  FLASHDOSE TECHNOLOGY. 
Flashdose technology has been patented by “FUIS” nurofenmeltlet, a 
new from of ibuprofen as melt in mouth tablets, prepared using flashdose 
technology is the first commercial product launched by “Bisavail Corporation”. 
Flash dose tablets consist of self bindingsheraform matrix termed as “FLOSS”. 
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Shear form matrices are prepared by flash heat processing (Alokkumar Gupta 
et al., 2011 and PoojaMathur et al., 2010). 
5. SHEARFORM TECHNOLOGY.
It’s based on preparation of floss that is known as shear form matrix, 
which is produced by subjecting a feedstock containing a sugar carrier by flash 
heat processing. In this process, sugar is simultaneous subjected to centrifugal 
force and to a temperature gradient, which raises the temperature of the mass 
to create an internal, flow condition, which permits part of it to move with respect 
of mass. The flowing mass exists through the spinning head they flings the 
floss. The floss so produced is amorphous in nature so it is further chopped and 
recrystalised by various techniques to provide uniform flow properties and thus 
facilitate blending. The recrystalised matrix is than blended with other tablet 
excipients and an active ingredient. The resulting mixture is compressed into 
tablet. The active ingredient and other excipients can be blended with floss 
before carrying out recrystallization. The shearform floss when blended with the 
coated or uncoated microsphreres, is compressed into flashdose or EZ chew 
tablets (Srivastava Saurabh et al.,2012 and Harendra et al., 2014). 
6. WOWTAB TECHNOLOGY.
Yamanouchi’s WOWTABR (without water) technology employs a 
combination of saccharides to produce fast dissolving tablets using 
conventional granulation, blending drying and direct compression of  tablets. 
Taste masking is provided by the combination of one or more sugar like 
excipients or microencapsulation of the active ingredients. These tablets exhibit 
significant hardness allowing packaging in conventional bottles or blisters 
(Harendra et al., 2014). 
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7. FLASHTAB TECHNOLOGY. 
Program pharm laboratories have patented the flashtab technology, 
Tablet prepared by this system consists of an active ingredient in the form of 
micro crystals. Drug micro granules maybe prepared by using the  conventional 
techniques like coacervation, micro encapsulation and extrusion 
spheronisation.  All the processing utilized conventional tableting technology. 
(Aloe Kumar Gupta et al., 2012). 
8. DISPERSIBLE TABLET TECHNOLOGY 
Lek, Yugoslavia patents this technology. It offers development of MDTs 
with improved dissolution rate by incorporating 8-10%of organic acids and 
disintegrating agents. Disintegrating agent facilitates rapid swelling and good 
wetting capabilities to the tablets that results in quick disntergration. 
disintegrants include starch, modified starches, microcrystalline cellulose, 
alginic acid, cross linked sodium carboxy methyl Cellulose and cyclodextrins 
combination of disintegrants improves disintegration of tablets usually less than 
1 minute (Aloe Kumar Gupta et al., 2012). 
9. FROSTA TECHNOLOGY. 
This technology patents by akina. It utilizes the concept of formulating 
plastic granules and compressing at low pressure to produce strong tablets with 
high porosity. Plastic granules composed of: porous and plastic material, water 
penetration enhancer and binder .the process involves usually mixing the porous 
plastic material with water penetration enhancer and followed by granulating with 
binder. The tablets obtained have excellent hardness and rapid disintrgration 
time ranging from 15 to 30 Sec depending on size of tablet. 
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10. PHARAMABURST TECHNOLOGY. 
SPI pharma, new castle, patents this technology. It utilizes the co 
processed excipients to develop MDTs, which dissolves within 30-40 s. this 
technology involves dry blending of drug, flavor, and lubricants followed by 
compression into tablets. Tablets obtained have sufficient strength so they can 
be packed in blister packs and bottles. (Harendra et al.,2014) 
11. OROQUICK TECHNOLOGY. 
 The oraquick ODT formulation utilizes a patented taste masking 
technology by KV pharmaceutical company, who claims that its taste masking 
technology ie. Microsphere technology (micromask) has superior mouth feel 
over taste masking alternatives. The taste masking process does not utilize 
solvents of any kind and therefore leads to faster and superior efficient 
production. Tablet with significant mechanical strength without distrupting taste 
masking are obtained after compression. Oraquick claims quick dissolution in 
matter of seconds with good taste masking. There are no products yet in the 
market using oraquick Technology, but KV pharmaceutical  has products, 
having different classes of drugs such as analgesics, cough and cold, 
psychotics and anti infective, in developmental stage (Sharma Deepak et al., 
2012). 
12. QUICK-DIS TECHNOLOGY. 
Lavipharm has invented an ideal intra-oral mouth dissolving drug 
delivery system, which satisfies the unmet needs of the market. The novel intra-
oral drug delivery system, trademarked quick-disTM, is Lavipharm” Proprietary 
patented technology and is a thin flexible, and quick dissolving film. The film is 
placed on the top or the floor of the tongue. It is retained at the site of application 
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and rapidly releses the active agent for local and or systemic absorption. The 
typical disintegration time is only 5 to 10 seconds for the quick-Dis TM film with 
a thickness of 2mm. the dissolving time is around 30 seconds for quick DisTM 
film with a thickness of 2mm (Deepack et al., 2012). 
13. NANOCRYSTAL TECHNOLOGY. 
This is patented by Elan, king of Prussia. Nano crystal technology 
includes lyophilization of colloidal dispersions of drug substance and water 
soluble ingredients filled into blisters pockets. This method avoids 
manufacturing process such as granulation, blending   and tableting which is 
more advantages for highly potent and hazardous drugs. As manufacturing 
losses are negligible, this process is useful for small quantities of drug 
(Tejvirkaur et al., 2011) 
14. ZIPLETS/ADVATAB TECHNOLOGY. 
It utilizes water insoluble ingredient combined with one or more effective 
disintegrants to produce MDT with improved mechanical strength and  optimal 
disintegration time at low compression force. 
15. CEFORM TECHNOLOGY. 
 This technology involves preparation of microspheres of active drugs. 
Drug material alone or in combination with other pharmaceutical substance and 
excipients is placed into a precision engineered rapid spinning machine. The 
centrifugal force comes into action, which throw the dry blend at high speed 
through small heated openings. Due to the heat provided by carefully controlled 
temperature, drug blend liquefies to form asphere, without affecting the drug 
stability. The microspheres are thus formed are compressed into tablets. As the 
drugs and  excipients both can be processed simultaneously, it create a unique 
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micro environment in which the material can be incorporated into the 
microspheres that can alter the characteristics of the drug, such as enhancing 
solubility and stability (Swami M. Velmanickam et al., 2010). 
16. QUICKSOLV TECHNOLOGY. 
 This technology used two solvents in formulating a matrix, which 
disintegrates instantly. Methodology includes dissolving matrix components in 
water and the solution or dispersion is frozen. Then dry the matrix by removing 
water using excess of alcohol (solvent extraction). Thus the product formed has 
uniform porosity and adequate strength for handling. 
17.LYO TECHNOLOGY 
 Lyo technology is patented by pharmalyoc. Oil in water emulsion is 
prepared and placed directly into blister cavities followed by freeze drying. Non 
homogeneity during freeze drying is avoided by incorporating inert filler to 
increase the viscosity finally the sedimentation. High proportion of filler reduces 
porosity of tablets due to which disintegration is lowered (Srivastava Saurabh 
et al., 2012 and Deepak et al.,2012). 
INGREDIENTS TO BE USED FOR ORAL DISINTERGRATING TABLET 
 Important ingredients that are used in the formulation of fast 
disintegrating tablets should allow quick release of the drug, resulting in faster 
dissolution. This includes both the active and inactive   ingredients excipients 
balance the properties of the actives in fast disintegrating tablets. 
Binders: 
 The choice of a binder is critical in a fast dissolving formulation for 
achieving the desired sensory and melting characteristics, and for the faster 
release of active ingredients. Binders keep the composition of these fast 
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dissolving tablets together during the compression stage.  The right selection 
of a binder or combination of maintain the integrity and stability of the tablet. 
Binders can either be liquid, semisolid, solid or mixtures of varying molecular 
weights such as poly ethylene glycol. As binding capacity of the binder 
increases, disintegrating time of the tablet increases and this counter act the 
rapid disintegration. 
Lubricants: 
 Lubrications are used for to reduce the friction during compaction and 
ejection of tablets in present study magnesium stearate and talc were used as 
lubricant e.g. stearic acid, magnesium stearate, poly ethylene glycol, liquid 
paraffin, magnesaiumlauylsulfate(Brahma Reddy D.R et al., 2011). 
 Bulking agent:  
The material contributes functions of a diluents, filler and cost reducer. 
Bulking agents improve the textural characteristics that in turn enhance the 
disintegration in the mouth, besides; adding bulk also reduces the 
concentrations of the active in the composition. The recommended bulking 
agents for this delivery system should be more sugar based such as mannitol, 
poly dextrose, lactate and starchhydrolysate for higher aqueous solubility and 
good sensory perception. 
Flavors and Sweeteners: 
 Flavors are peppermint, aromatic oil, clove oil, anise oil, eucalyptus oil, 
thyme oil, vanilla oil, and citrus oil. The addition of these ingredients assists in 
overcoming bitterness and undesirable tastes of some active ingredients. 
Formulators can choose from a wide range of sweeteners including sugar, 
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dextrose and fructose, as well as non nutritive sweeteners such as aspartame, 
sugar alcohols and sucralose (Brahma Reddy D.R et al., 2011). 
Role of superdisitegrants: 
 A “Superdisintegrants” is an excipient, which is added to tablet or 
capsule blend to aid in the breakup of the compacted mass, when put in to a 
fluid environment. Superdisintegrants improve disintegration dissolution of the 
tablets. It is essential to choose an optimum concentration of superdisintegrants 
so as to tablets. Superdisintegrants, provide rabid disintegration due to 
combined effect of swelling of superdisintegrants the weeed of the carrier 
increases, this promoted the wettability and dispersibility of the system, thus 
enhancing the disintegration and dissolution. The optimum concentration of the 
superdisintegrants can be selected according to the critical concentration of the 
disnitegrants. Superdisintegrants which are effective at low concentration and 
have greater disintegrating efficiency and they are more effective 
intragranularly. But have one drawback that it is hygroscopic therefore not used 
with moisture sensitive drugs (HardikShihora et al., 2011 and Sharma 
Deepak et al., 2012). 
 
FACTORS AFFECTING ACTION OF DISTEGRANTS 
• Percentage of Disintegrate Present in The Tablets 
• Type of Excipients Present In The Tablets 
• Combination of disintegrants 
• Presence of surfactant 
• Hardness of tablet 
• Nature of drug substance 
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• Mixing and screening
Ideal characteristics of superdisintegrants: 
• Poor gel formation
• Good compressibility
• Inert
• Non-toxic
• Good flow Properties
• Requirement of least quantity
• Good mouth feel
• Particle size and  different super disintegrants
 MECHANISM OF ACTION OF SUPER DISINTEGRANTS 
 The tablet breaks to primary particles by one or more of the mechanism 
listed below: 
1. By swelling
2. By capillary action
3. Due to  disintegrating particle /particle repulsive forces
4. Due to deformation
5. Due to release of gases
 By Swelling: 
1. Tablets with high porosity show poor disintegration due to lack of adequate
swelling force. On the other hand, sufficient swelling force is exerted in the 
tablet with low porosity. It is worthwhile to note that if the packing fraction 
is very high. Fluid is unable to penetrate in the tablet and disintegration is 
again slows down. 
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Mechanism of action of superdisintegrants by swelling  
 
 
 
 
 
 Disintegration of tablet by deformation and repulsion 
Disintegrant  pulls water 
into the pores and reduces 
the physical bonding 
forces between particles
Particles swell and break up 
the matrix from within, 
swelling sets up. Localized 
stress spreads through out 
the matrix 
Particles swell to pre –
compression size and 
break up matrix 
Water is drawn into pores 
and particles repel each 
other due to the resulting 
electrical force 
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2. By Capillary Action: 
Disintegration by capillary action is always the first step. When we put 
the tablet into suitable aqueous medium, the medium penetrates into the tablet 
and replaces the air absorbed on the particles, which weakens the 
intermolecular bone and breaks the tablet into particles. Water uptake by tablet 
depends upon hydrophilicity of the drug/excipient and on tableting conditions. 
For these types of disintegrants maintenance of porous structure and low 
interfacial tension towards aqueous fluid is necessary  which helps in 
disintegration by creating a hydrophilic network around the drug particles. 
3. Due to Disintegrating Particle/Particle Repulsive Forces: 
Another mechanism of disintegration attempts to explain the swelling of 
tablet made with ‘non swellable’ disintegrants. Guyot-Hermann has proposed a 
particle repulsion theory based on the observation that non swelling particle 
also caused is integration  of tablets. The electric repulsive forces between 
particles are the mechanism of disintegration and water is required for it. 
Researchers found that repulsion is secondary to wicking. 
4. Due to Deformation: 
Hess had proved that during tablet compression, disintegrated particles 
get deformed and these deformed particles get into their normal structure when 
they come in contact with aqueous media or water. Occasionally, the swelling 
capacity of starch was improved when granules were extensively deformed 
during compression. Disintegration of tablet by repulsion: Another mechanism 
of disintegration attempts to explain the welling of tablet made with “non 
swellable” disintegrants. Guyot Hermann has proposed a particle repulsion 
theory based on the observation that no swelling particle also cuses 
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disintegration of tablets. The electric repulsive forces between particles are the 
mechanism of disintegration and water is required for it. Researchers found that 
the methods of incorporating disintegrants into tablets. This increase in size of 
the deformed particles produces a breakup of the tablet. This maybe a 
mechanism of starch and has only recently begum to be studied (Tejvir Kaur 
et al., 2011) 
5. Due to Release Of Gases:
Carbon-dioxide released within tablets on wetting due to interaction 
between bicarbonate and carbonate with citric acid and tartaric acid. The tablet 
disintegrates due to generation of pressure within the tablet. This effervescent 
mixture is used when pharmacist needs to formulte very rapidly dissolving 
tablets or fast disintegrating tablet. As these disintegrants are highly sensitive 
to small changes in humidity level and temperature, strict control of environment 
is required during manufacturing of the tablets. The effervescent blend is either 
added immediately prior to compression or can be added into two separate 
fraction of formulation (NishthaTiwariet al., 2012). 
6. By Enzymatic Action:
Here, enzymes present in the body act as disintegrants. These  enzymes 
destroy the binding action of binder and helps in disintegration. Actually due to 
swelling, pressure exerted in the outer direction or radial direction, it causes 
tablet to burst or the accelerated absorption of water leading to an enormous 
increase in the volume of granules to promote disintegration. 
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Figure.7. Disintegration Mechanism Of Superdisintegrant Materials 
 
Internal Addition (Intragranular): 
In internal addition method, the disintegrant is mixed with other powders 
before wetting the powder mixtures with the granulating fluid. Thus the 
disintegrant is incorporated within the granules. In dry granulation method, the 
disintrgrant is added to other excipients before compressing the powder 
between the rollers. 
External Addition (Extra granular): 
In external addition method, the disintegrant is added to the sized 
granulation with mixing prior to compression. 
Partly Internal and External: 
In this method, part of disintegrant can be added internally. This results 
in immediate disruption of the tablet into previously compressed granules while 
the disintegrating agent within the granules produces additional erosion of the 
granules to the original powder particles. This method can be more effective. If 
both intragranular and extragranular methods are used, extragranular portion 
break the tablet into granules and the granules further disintegrate by 
intragranular portion to release the drug substance into solution. However, the 
portion of intragranulardisintegrant (in wet granulation processes) which 
reduces the activity of the disintegrant. The intragranular disintegrant tends to 
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retain good disintegration activity in case of compaction process as it does not 
involve its exposure to wetting and drying (MohitMangal et al., 2012). 
Selection Criteria for Superdisinitegrant 
 Although superdisintegrants primarily affect the rate of disintegration, but 
when used at high levels it can affect mouth feel, tablet hardness and friability. 
Hence, various ideal factors to be considered while selecting an appropriate 
superdisintegrants for a particular formulation should: 
1. Proceed for rapid disintegration, when tablet comes in contract with 
saliva in the mouth/oral cavity. 
2. Be compactable enough to produce less friable tablets. 
3. Produce good mouth feel to the patients. Thus, small particle size is 
preferred to achieve patient compliance. 
4.  Have good flow, since it improves the flow characteristics of total blend 
(Vimal V.V.et.al.,2013). 
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CHAPTER II 
LITERATURE REVIEW 
 
Gupta M.M. et al., 2014, formulated and evaluated fast disintegrating 
combination tablet of levocetrizinedihydrochloride and mentelukast sodium by 
using direct compression method. The tablets were prepared using micro 
crystalline cellulose as diluent along with crospovidone, croscarmellose sodium 
and sodium starch glycolate as a super distegrants.  The disintegration time 
and dissolution study and it was concluded that the tablet formulation prepared 
with 2% CCS showed better distintegration time in comparison with other 
formulation. 
 
Sateesh Kumar Vemula et cl., 2014, formulated and evaluated oral dispersible 
tablets of the meclizine hydrochloride using sublimation method to enhance the 
dissolution rate, with the help to superdisintegrants and camphor as sublimating 
agent, the formulation with crospovidone used as superdisintegrants exhibited 
fast release profile of about 98.61% in 30 min with 47 sec when compared with 
other formulations and marketed tablet. 
 
Nagendrakumar. D et al., 2014, formulated and evaluated oral dispersible 
tablets of metoclopramide hydrochloride developed by the direct compression 
method using different concentrations of crospovidone (1.5% - 7.5%) as 
synthetic superdisintegrant and isolated mucilage of hibiscus rosasinensis 
(1.5% - 7.5%) as natural superdisintegrant.  Results revealed that the 
formulation containing 7.5% of crospovidone and formulation containing 7.5% 
of hibiscus rosasinensis was found to be promising formulation. 
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Subbiah B.V. et al., 2014, formulated and evaluated oral dispersible tablets by 
direct compression method using trihexyphenidyl hydrochloride as a model 
drug.  Oral dispersible tablets of trihexyphenidyl hydrochloride formulated using 
different concentration of superdisintegrants like sodium starch glycolate and 
crospovidone.  The formulation prepared with sodium starch glycolate as 
superdisintegrants in the concentration of 6% w/w shows rapid disintegration 
and 99.9% of drug released within 35 min when compared with other 
disintegrants used in. 
 
SaiPadmininBolla et al., 2014, the development of oro-dispersible tablets of 
clonazepam using natural superdisintegrants like Mucilage of hibiscus 
rosasinensis leaf and seeds of ocimumbasilicum were extracted, evaluated for 
the organoleptic, physicochemical parameters.  The dried mucilage was used 
as superdisintegrant for the preparation of orodispersible tablets by direct 
compression method.  The optimized formulation was subjected to wet 
granulation using PVP in IPA as the dry binder.  The tablets containing 5% w/w 
dried mucilage of ocimumbasilicum was found to be the best formulation which 
disintegrated in 22 sec with 99.8% drug release. 
 
Ameer S.Sahib et al., 2013, formulated and evaluated oral dispersible tablets 
of phenobarbital is an antiepileptic drug used in the treatment of epilepsy.  Oral 
dispersiblephenobarbitone tablets were prepared using direct compression 
method technique depends on using three different superdisintegrants with 
different concentrations (5-15% w/w) i.e., sodium starch glycolate, 
croscarmelose, crospovidone.  Cropovidone 10% with microcrystalline 
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cellulose (25%) gave the good acceptable friability (0.53±0.25%) with least 
disintegration time (12.07±0.23 sec) and best flow property. 
 
Venkatesh K. et al., 2013, baclofen is a muscle relaxant and describe as 
(3RS)-4amino-3-(4-clorophemyl) butanoic acid. Oral bioavailability of baclofen 
is around 80% and having half-life 4 hrsdesign of oral dispersible tablets of 
baclofen were prepared by direct compression and solid dispersion method.  
The results concluded that oral dispersible tablets of baclofen showing 
enhanced dissolution will lead to improved bioavailability and effective therapy 
using solid dispersion method. 
 
Tansande J.B. et al., 2013, formulated and evaluated oral dispersible tablets 
of tomoxicam were prepared with natural and synthetic superdisintegrant by 
direct compression method. The natural superdisintegrant used were banana 
powder, soy polysaccharide 8% crospovidone showed disintegration time 10 
seconds to 12 seconds respectively.  The formulation with soy polysaccharide 
showed more than 90% drug release respectively.  It was concluded that 
natural superdisintegrant has better disintegration time, more water absorption 
and faster drug release. 
 
Mahesh Gattani et al., 2013, formulated and evaluated oral dispersible tablets 
of zolmitriptan.  It is to co process tablet excipients by rotary evaporation 
method to create mixtures that can help in achieving direct compression 
optimum disintegration time along with required hardness & friability of orally 
disintegrating tablets.  Co procession using of lactose with other excipients was 
done by rotary evaporation method using water as solvent.  The co-processed 
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excipients were evaluated for pre compression and post compression 
properties. 
 
Mangesh M.Kumar et al., 2013, formulated and evaluated oral dispersible 
tablets of atenolol were prepared by direct compression technique using two 
different superdisintegrants in combination by co-process mixing and physical 
mixing.  Croscarmellose sodium and crospovidone were used as super 
disintegrants in combinations in the different ratio (1:1, 1:2, 1:3).  Oral 
dispersible tablets of atenolol were prepared using the co-processed super 
disintegrants and evaluated for pre-compression and post compression 
parameters.  Among the designed formulations, the formulation (CP) containing 
4% w/w of co-processed super disintegrants (1:1) mixture of crospovidone and 
crosmellose sodium emerged as the overall best formulation based on drug 
release characteristics in pH 6.8 phosphate buffer crystalline cellulose. 
 
Ramu. A et al., 2013, formulated and evaluated rosuvastatin calcium is a 
selective and competitive inhibitor of HMG-CoA reductase, mainly used in the 
treatment of hypercholesterolemia, hypertriglyceridemia and atherosclerosis.  
Resuvastatin poorly soluble in water was made to enhance solubility, 
dissolution rate and oral bio availability by formulating it as solid dispersions 
using various techniques with polyethylene glycol (PEG) 6000 as a carrier.  Oral 
dispersible tablets of rosuvastatin were prepared with super disintegrants like 
sodium starch glycolate, croscarmellose sodium, pre gelatinized starch and 
mannitol from the optimized solid dispersions. 
Lavande J.P. et al., 2013, formulated and evaluated fast/mouth dissolving 
tablet of olmesartanmedoxomil by direct compression method.  
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Olmesartanmedoxomil 20 mg using synthetic and natural superdisintegrants 
like, sodium starchglycolate, croscarmellose, crospovidone and 
plantagoovatamucilage in different concentrations (5, 7.5 and 10mg).  The 
prepared formulation were evaluated and compared to synthetic 
superdisintegrant with plantagoovata showed faster release of the drug. 
 
VenkatchalanRajuPeetha et al., 2013, formulated and evaluated mouth 
dissolving tablets of nimodipine drug prepared by using three different 
superdisintegrantscrosscarmellose sodium, sodium starch glycolate, 
crospovidone.  Each superdisintrgrate was used in different concentration like 
2.5% 5% w/w, 7.5% w/w.  The result concluded 7.5% w/w showed better 
optimum results. 
 
Venkateswarlu. B et al., 2013, formulated and evaluated oral dispersible 
tablets of amotidine using combined approach of complexing agent and 
superdisintegrant by direct compression method.  The super disintegrate was 
used in different concentration like 2.5w/w, 5% w/w, 7.5% w/w.  The prepared 
tablets were dried under oven for evaporate the complexing agent and drug 
release.  All the formulation disintegrated within 10-60 seconds with 99.3% drug 
release finding the result was concluded three formulation containing 
complexing agent and superdisintegrants showed better performance in 
disintegration and drug release profile. 
Kamal Saroha et al., 2013, the oral dispersible tablets of amoxicillin trihydrate 
were prepared by direct compression technique using microcrystalline cellulose 
sodium starch glycolate and croscarmillose sodium used as synthetic 
superdisintegrants.  Eight formulations were prepared using different 
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concentrations of superdisintegrants and were investigated for their effect on 
the disintegration time and dissolution rate of the tablets.  It was found that 
tablets of batch (blend containing CCS 60mg) showed better disintegrating 
property as well as % drug release (99.78% within 25 min) than the most widely 
used. 
 
Abdul Hassan Sathali A. et al., 2012, formulated and evaluated Fast 
dissolving tablets of lamivudine to prevent mother to child transmission (MTCT) 
of HIV virus in perinatal infants.  The tablets were prepared by direct 
compression method, using various superdisintegrants like sodium starch 
glycolate, croscarmallose sodium, and crospovidone at various concentrations 
(2%-10%).  From the results of post compression studies for tablets for tablets 
of all formulations, it was concluded that the formulation containing 10% 
crospovidone as superdisintegrants emerged as overall best formulation with 
lowest disintegration time and highest drug release rate. 
 
Venkata Naveen Kasagana et al., 2012, formulated and evaluated in oral 
dispersible tablets of piroxicam by using three different superdisintegrants 
namely crospovidone, sodium starch glycolate and pre gelatinized starch with 
three different concentrations (3%, 4% and 5%) and (without super disintegrant) 
were analysed.  The results revealed that the formulation containing 
crospovidone (5%) as super disintegrant was better one which satisfied all the 
requirements necessary for oral dispersible tablets. 
 
Mali P.A. et al., 2012, formulated evaluated oral dispersible tablets of 
carbamazepine is very low solubility in biological fluid & poor bioavailability after 
oral administration.  The tablets were prepared with the hep of super 
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disintegrants such as crospovidone, sodium starch glycolate& pre gelatinized 
starch.  With effect of superdisintegrants among all formulation was considered 
best.  The result concluded that FDT of poorly soluble drug carbamazepine, 
showed enhanced dissolution lead will lead to improved bioavailability, 
effectiveness & hence better patience compliance. 
 
RajeshreePanigrahil et al., 2012, oral dispersible tablets of lisinopril were 
designed using combination of synthetic superdisintegrants like croscarmellose 
sodium, crospovidone and sodium starch glyclolate in a ratio of 5:10 and 10:5 
respectively by direct compression method.  The formulation of lisinopril 
containing 10% crospovidone and 5% croscarmellose showed disintegration 
time of 50 sec respectively with 99% drug release within 30 min.  The results 
showed that superdisintegrants used in combinations exhibited better 
disintegrating property. 
 
CinmayAnand. L et al., 2012, formulated and evaluated oral dispersible tablet 
of tolfenamic acid.  The solubility of tolfenamic acid was improved by co-
micronized with microcrystalline cellulose and surfactants as sodium lauryl 
sulfate.  One reference formulation was also manufactured with conventional 
method using non-micronized tolfenamic acid with surfactants. The formulation 
was than evaluated for various physical and analytical properties of rapid 
dispersible tablets.  Results obtained showed that there was significant 
increase in dissolution rate of drug in first 5 minutes of time interval as compare 
to reference formulation.  The wetting and dispersion properties of formulations 
also found superior as compare to reference formulation. 
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AnieVijetha K. et al., 2012, formulated and evaluated oral dispersible tablets 
(FDT) of isradipine by employing different technologies like liquid solid by 
improving wetting, sublimation by creating porous environment, effervescent 
and super disintegrant by breaking the tablet fast.  The FDT of isradipine were 
also prepared by adopting direct compression method.  The isradipine FDT of 
isradipine were also prepared by adopting direct compression method.  The 
isradipine FDTs of effervescent technology was showing immediate release 
with T90% within 4 min and hence the effervescent technology was proved to 
be the promising in comparison with other technology types. 
 
SudheshnaBabuSukhavasi et al., 2012, formulated and evaluated the oral 
dispersible tablets of amlodipine besylate tablets using Fenugreek seed 
mucilage and ocimumbasilicum gum as a natural superdisintegrating agents to 
achieve quick onset of action, is to increase the water uptake with in shortest 
wetting time and there by decrease the disintegration time of the tablets by 
simple and cost effective direct compression technique.  The best formulations 
FFGK5 & FOB5 have shown good disintegration time, hardness and friability.  
The best formulations were also found to stable. 
 
DevendraRevanandRaneet et al., 2012, formulated and evaluated oral 
dispersible tablets of albendazole is broad spectrum anthelmintic use against 
many helminths.  Oral dispersible tablets prepared by direct compression 
method. The prepared tablets were subjected for post compressional 
evaluation.  Among all, the formulation containing 5% w/w super 
disintegrantcros povidone and 20% w/w microcrystalline cellulose was 
considered to be best formulation, which release up to 99.097%in 40 min. 
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Nilesh Jain et al., 2012, formulated and evaluated oral dispersible tablets of 
ciprofloxacin using  asuperdisintegrants like crospovidone and sodium starch 
glycolate.  The in vitro disintegration time of the best fast disintegration tablets 
was found to be within 36 seconds.  Tablets containing crospovidoe (40%) 
exhibits quick disintegration time than tablets containing sodium starch 
glycolate.  The fast disintegrating tablets of ciprofloxacin with shorter 
disintegration time, acceptable taste and sufficient hardness could be prepared 
using crospovidone and other excipients at optimum concentration. 
 
Swati ChangdeoJagdalel et al., 2012,The main objective of the study was to 
enhance the dissolution of nifedipine, a poorly water soluble drug by 
betacyclodextrin inclusion complexation of nifedipine with β-cyclodextrine was 
1:1. Binary complex was prepared by different methods and was further 
characterized using XRD, DSC and FT-IR.  A saturation solubility study was 
carried out to evaluate the increase in solubility of nifedipine.  The optimized 
complex was formulated into fast-dissolving tablets by using the 
superdisintegrants Doshion P544, pregelatinized starch, crospovidone, sodium 
starch glycolate and croscarmellose sodium by direct compression.  The result 
revealed that completed the tablets showed an enhanced dissolution rate 
compared to pure nifedipine. 
Amit Modi et al., 2012, formulate for FDT of diclofenac sodium by using various 
superdisintegrant like sodium starch glycolate, croscarmellose sodium and 
crosspovidone (polyplasdone XL) followed by direct compression technique.  It 
was concluded that the batch which was prepared by using combination of 
crosspovidone and sodium starch glycolate as a superdisintegrant showed 
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excellent dsintegration time, enhance dissolution rate better taste masking and 
hence lead to improved efficacy and bio avaibility of drug. 
 
SaimaErumet et al., 2011, formulated and evaluated oral dispersible tablets of 
aspirin prepared by direct compression method, contained excipients that 
comprises of lactose, cornstarch, aerosol.  The results were compared with 
other brands.  The formulate asprin tablets by direct compression method using 
fewer excipients and compared that formulation with the other brands.  The 
studied formulation showed close resemblance with the available marketed 
brands. 
 
Chowdary K.P.R. et al., 2011, formulated and evaluated oral dispersible 
tablets of nimulslide by wet granulation and direct compression method, poor 
solubility and dissolution rate.  The developed nimulslide rapidly dissolving 
tablet formulated with starch phosphate by direct compression method, Tablets 
formulated employing starch phosphate as directly compressible vehicle.  
Nimulide-starchphosphate (1:2) solid dispersion is gave much hogher 
dissolution rates and disintegrating values when compared to others. 
 
Basawaraj S. et al., 2011, formulated and evaluated of oral dispersible tablets 
of granisetronehydrochloride is a selective 5H4 receptor antagonist, treatment 
of vomiting in cancer therapy.  Granisetrone prepared by direct compression 
method.  The prepared tablets were evaluated for pre compressional parameter 
such as hardness, friability, thickness, invitro dispersion time, wetting time, 
water absorption ratio and it was the prepared tablets were characterised by 
FTIR studies. 
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Chandrasekhar Patro et al., 2011, formulated and evaluated cetirizine 
hydrochloride mouth oral dispersible tablets using different concentrations of 
super disintegrants like crospovidone, croscarmellose sodium, sodium starch 
glycolate by direct compression method and evaluated.  The results indicated 
that tablets with 5% croscarmellose sodium was found to be optimized which 
provides maximum drug release (99%) and minimum disintegration time (less 
than 20 sec). Stability studies of optimized formulation revealed that formulation 
is stable. 
 
Himmat Singh et al., 2011, formulated and evaluated mouth dissolving tablets 
of carvedilol.  The solubility of carvedilol was enhanced with different ratios of 
PVP by the solvent evaporation method.  Invitro release profile of solid 
dispersion obtained in SGF without enzymes and pH6.8 phosphate buffer 
indicate that 100% drug release found within 20 minutes.  This solid dispersion 
was directly compressed into tablets using crospovidone, sodium starch 
glycolate, and croscarmellose sodium and potacrilin potassium in different 
concentration as a super disintegrant.  The prepared tablets containing the solid 
dispersion of carvedilol were found to have sufficient strength of 2.5-4 Kg/cm2 
which disintegrated in the oral cavity within 21 seconds contain crospovidone 
(5%) as super disintegrant. 
Govind K. Chandile et al., 2011, formulated and evaluated oral dispersible 
tablets of haloperidol were prepared using novel co-processed super 
disintegrants consisting of crospovidone and primogel in the different ratio (1:1, 
1:2 & 1:3) but direct compression technique.  Among all, the formulation 
crospovidone containing 4% w/w super disintegrant (1:1 mixture of 
crospovidone and primogel) was considered to be best formulation, which 
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release up to 99.21% in 12 min.  The present study demonstrated potentials for 
rapid absorption, improved bioavailability, effective therapy and patient 
compliance. 
 
Indhumathi, D. et al., 2011, formulated and evaluated oral dispersible tablets 
of fluoxetine using different super disintegrants (Sodium starch glycolate, 
croscarmellose, crospovidonepregelatinized starch) by wet granulation 
method.  In vitro dissolution studies shows the release is in the following order 
of super disintegrantscrospovidone>pregelatinized starch >croscarmellose> 
sodium starch glycolate.  From the study it has been found and concluded, 
crospovidone at a concentration of 5% w/w shows maximum in-vitro dissolution 
profile, this is also confirmed by in vivo pharmacokinetic studies, and hence it 
emerged as the overall best formulation hence suitable for preparing oral 
dispersible tablet of fluoxetine. 
 
ShireeshKiran 1, R. et al., 2010, formulated and evaluated mouth dissolving 
tablets of glipizide with sodium glycolate, crospovidone and pregelatinized 
starch.  Oral dispersible tablets of the sodium starch glycolate, crospovidone 
and pregelatinized starch were prepared by direct-compression method in 
different concentrations.  Dissolution profile indicated that the complete drug 
release in 20 min from all the formulation tested.  The oral dispersible tablet of 
glipizide by using the pregelatinized starch showed with excellent in vitro and 
in vivo dispersion time and drug and release, as compared to other 
formulations. 
 
Prameela Rani A. et al., 2010, formulated and evaluated oral dispersible 
tablets metformin hydrochloride with help of isphagula husk, natural 
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superdisintegrants and cropovidone, synthetic superdisintegrant.  The 
disintegration time in the oral cavity was also tested and was found to be around 
10 sec.  based dissolution rate, it can be rated as isphagula husk 
>crospovidone.  Hence ishagula husk was recommended as suitable 
disintegrant for the preparation of direct compression melt-in-mouth tablets of 
metformin hydrochloride. All the dissolution parameters were calculated and 
compared (Glycophage).  It was concluded that the tablets have a acceptable 
hardness, rapid disintegration in the oral cavity with enhanced dissolution rate 
and better patient compliance. 
 
Raghavendra Rao, N.G. et al., 2010, formulated and evaluated oral dispersible 
of felodipine.  Felodipine is practically insoluble in water prepared by direct 
compression method.  Effect of superdisintegrants (such as croscarmellose 
sodium, and crospovidone) on wetting time, disintegrating time, drug content, 
in vitro release, and stability parameters have been studied. Tablets prepared 
by solid dispersion with mannitol showed higher hardness than other tablets 
prepared by solid dispersion with PVP and PEG.  Disintegration time of tablets 
prepared by solid dispersion using mannitol, increased significantly (p<0.05).  
From this study, it can be concluded that dissolution rate of felodipine could be 
enhanced by tablets containing solid dispersion by direct compression 
technique. Tablets containing solid dispersion with PVP of ration 1:4 (p3), with 
PEG of ratio 1:4 (E3) and with mannitol of ratio 1:9 (M4) yielded best results in 
terms of dissolution rate. 
 
Shailsh Sharma et al., 2010, formulated and evaluated oral dispersible tablets 
of promethazine theoclate.  The solubility of promethazine theoclate was 
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increased by using β-cycloclodextrin, crospovidone, camphor for using direct 
compression method. The optimized tablet should be prepared with an optimum 
amount of β-cyclodextrin (3.0 mg), camphor (3.29 mg) and crospovidone (2.61 
mg) which disintegrated in 30s, with a friability of 0.60% and drug release of 
89% in 5 min.  The optimized approach aided both the formulation of oral 
dispersibletheoclate tablets and the understanding of the effect of formulation 
processing variables on the development of the formulation. 
 
Suhas M.K. Kode et al., 2010, mouth dissolving tablets of losartan potassium 
to achieve a better dissolution rate and further improving the bioavailability of 
the drug.  Mouth dissolving tablets prepared by direct compression and using 
super disintegrants like Polyplasdone XL 10,Croscarmellose sodium and 
Explotab in different concentration and evaluated for the pre-compression 
parameters such as bulk density, compressibility, angle of repose etc.  The 
prepared batches of tablets were evaluated for hardness, weight variation, 
friability, drug content, disintegration time and in-vitro dissolution profile and 
found satisfactory.  Among all, the formulation F3 containing 5% w/w 
superdisintegrantPolyplasdone XL 10 was considered to be best formulation, 
which release up to 99.26% in 12 min. 
 
Keny. R.V. et al., 2010, mouth disintegrating tablets rizatriptan benzoate were 
prepared by direct compression method employing crospovidone, 
carboxymethylcellulose calcium, Indion 414 and Indion 234 as 
superdisintegrants in different ratios, either alone or in combination. The 
formulations used, Indion 234 >Crospovidone >carboxymethylcellulose calcium 
>Indion 414.  The tablets containing crospovidone and calcium CMC in 
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combination, showed faster disintegration than tablets containing crospovidone 
alone,  calcium CMC alone and their combinations with other 
superdisintegrants.  Indion 414 showed comparable disintegration when used 
alone and in combination with Crospovidone, but fastest comparable 
disintegration when used alone and in combination with Crospovidone, but 
faster disintegration was seen in its combination with calcium CMC than with 
others.  Indion 234 also showed satisfactory disintegration time when used 
alone (18-19) and in combination with Crospovidone (15-16s), compared to its 
combination with other superdisintegrants.  Rizatriptan Benzoate release was 
significantly faster from all the prepared formulations as compared to marketed 
conventional tablet formulation.  In conclusion, s table, effective and pleasant 
tasting mouth disintegrating tablet, exhibiting an excellent disintegration time 
and dissolution profile, was formulated using a combination of crospovidone 
(4%) and Indion 234 (2%) as superdisintegrants.  Even though the excipients 
employed are well known and established, they have not been used with 
rizatriptan benzoate for formulating mouth disintegrating tablets. 
Patel, B.P. et al., 2010, the mouth dissolving tablets of cinnarizine were 
prepared by superdisintegrants addition usigcrospovidone, croscarmellose 
sodium and L-HPC in different concentration like 5%, 7.5% and 10%. There are 
total nine formulations were prepared and evaluated for various parameters. 
Formulation B9 containing L-HPC in concentration of 10% showed minimum 
disintegration time, wetting time as compare to other formulations.  Results of 
dissolution studies showed that total drug was released in 6 min.  The results 
shown that disintegration time was increased in the manners of L-
HPC<crospovidone<croscarmellose sodium. 
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Jain C.P. et al., 2009, formulated and evaluated oral dispersible tablets of 
valsartan were prepared using different superdisintegrants by direct 
compression method.  FDT disintegrant on disintegration behaviour of tablet in 
artificial saliva, pH 5.8 was evaluated.  Wetting time of formulations containing 
crospovidone was least and tablets showed fastest disintegration.  The drug 
release from FDTs increased with increasing concentration of super 
disintegrants and was found to be highest with formulations containing 
crospovidone.  The release of valsartan from FDTs was found to follow non-
Fickian diffusion kinetics. 
 
Shailendra Kumar Singh et al., 2009, formulated and evaluated oral 
dispersible tablets of omeprazole and domperidone with using pertinent 
disintegrants by direct compression method.  The tablets were prepared using 
mannitol as diluent and sodium sacchairn as sweetening agent along with three 
different levels of superdisintegrant used in kollidon CL, Ac-Di-Sol, drug and 
SSG. Omeprazole and domperidone were well resolved and the retention times 
were around 9.01 and 6.2 respectively.  From the results obtained, it can be 
concluded that the tablet formulation prepared with 4.76% Ac-Di-Sol (internally 
cross linked form of sodium carboxymethylcellulose) i.e., 10 mg showed 
disintegration time of 15 seconds in vitro.  Also the hardness, friability, 
dissolution rate and assay of prepared tablets (batch F7) were found to be 
acceptable according to standard limits. 
 
Kawtikar P.S. et al., 2009, formulated and evaluated oral dispersible tablets of 
tizanidine hydrochloride by using eudragit E100 as a taste making agent using 
mass extrusion technique for preparing taste masked granules.  The tablet was 
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prepared with three super disintegrants such as sodium starch glycolate, 
crsscarmellose sodium and crospovidone. Disintegration in oral cavity tested 
was found to be 22 seconds.  Other tablets were prepared by using camphor 
as sublimating agent.  It was concluded that tablets prepared by addition of 
superdisintegrants has less disintegration time than those prepared by 
sublimation method. 
Kevin C. et al., 2008, formulated and evaluated of oral dispersible tablets of 
aceclofenac poor aqueous solubility and hence poor bioavailability.  The effect 
of various super disintegrantssuch as sodium starch glucolate, cross 
carmellose sodium and pregelatinished starch (Starch 1500) prepared by wet 
granulation method.  The disintegration time of all formulation showed less than 
89 seconds.  Formulation containing equal amount of cross carmellose sodium 
and pregelatinized starch showed fastest disintegration than other formulations 
containing starch 1500, cross carmellose sodium and sodium starch glycolate 
in various proportions and the percentage drug release was 99.5 within 10 
minutes. 
Udya S. Rangole et al., 2008, formulated and evaluated rapidly disintegrating 
tablets of hydrochlorthiazide using different concentration (2%, 3%, 4%, and 
5%) of superdisintegrants like croscarmellose sodium and crospovidone by 
direct compression method.  Disintegration time and drug release were taken 
as the basis to optimize the rapidly disintegrating tablet.  Crospovidone in the 
concentration of 4% gave fastest disintegration in 16 seconds and showed 
100% drug release within 14 minutes were selected as the optimized 
formulation. 
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SheetalMalke et al., 2007,oxycarbazepine a new anticonvulsant drug.  Oral 
dispersible tablets of oxcarbazepine were prepared containing Avicel pH 102 
as a diluent and Ac-Di-Sol as a superdisintegrant by wet granulation process.  
Since the drug is poorly water soluble, drug release was tested in various media 
and the effect of surfactant on drug release was studied.  An effective, pleasant 
tasting and stable formulation containing 12% Ac-Di-Sol, 25% Avicel pH 10.2 
and 8.5 starch as a binder was found to have a good hardness of 4-4.5 kg/cm2, 
disintegration  time of 28±5s and drug release of not less than 90% within 30 
min.  The drug release was found to be comparable to the marketed dispersible 
tablet. 
 
Shagufta Khan et al., 2007, ondansetronhydrochloride to a rapid disintegrating 
tablet of the taste-masked drug.  Taste masking was done by 
complexingondansetrone hydrochloride with aminoalkyl methacrylate 
copolymer (Eudragit EPO) in different ratios by the precipitation method.  Drug-
polymer complexes were tested for drug content, in vitro taste in simulated 
salivary fluid of pH 6.2, and molecular property.  Complex that did not release 
drug in SSF was considered taste-masked and selected for formulation RDTs.  
The complex with drug-polymer ratio of 8:2 did not show drug release in SSF; 
therefore, it was selected.  The polyplasdone XL-10 7% wt/wt gave the 
minimum disintegration time.  The formulation containing spray-dried mannitol 
and microcrystalline cellulose in the ratio 1:1 and 7% wt/wtpolyplasdone XL-10 
showed faster disintegration, within 12.5 seconds, than the marketed tablet 
(112 seconds).  Tablets of batch F4 also revealed rapid drug release (90,60 
seconds) in SGF compared with marketed formulation (90,240 seconds; P G 
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.01). Thus, results conclusively demonstrated successful masking of taste and 
rapid disintegration of the formulated tablets in the oral cavity. 
Mahaja. H.S. et al., 2000, mouth dissolve tablets of sumatriptan succinate were 
prepared using disintegrants, sodium starch glycolate, carboxy methylcellulose 
sodium and treated agar by direct compression method.  The prepared tablets 
were evaluated for thickness, uniformity of weight, content uniformity, 
hardness, tensile strength, porosity, friability, wetting time, water absorption 
ratio, in vitro and in vivo disintegration time and in vitro drug release.  The 
tablets disintegrate in vitro and in vivo within 10 to 16s and 12 to 18s, 
respectively.  Almost 90% of drug were released from all formulations within 10 
min.  The formulations containing combination of sodium starch glycolate and 
carboxy methyl cellulose was found to give the best results. 
 
Hector Fausett et al., 2000, formulated and evaluated develop a rapidly 
disintegrating calcium carbonate tablet by direct compression method.  Calcium 
carbonate tablets were formulated on a carver press using 3 different forms of 
(Cal-Carb 4450 ®, Cal-Carb 4457®, and Cal-Carb 4462®).  The calcium 
concentration was determined by an atomic absorption spectrophotometer.  
Scanning electron microscopy was used to evaluate the surface topography of 
the granules and tablets.  Breakig strength of Cal-Carb4450®, Cal-Carb 4457®, 
and Cal-Carb 4462® tablets was in the range of 7.2 to 7.7 kg, as compared with 
a hardness of 6.2 kg and 10 kg for the commercially available calcium tablets 
citracal ® and Tums®, respectively. The disintegration time for the tablets 
presented in the order earlier was 4.1, 2.1, 1.9, 2.9 and 9.7 minutes, 
respectively.  The dissolution studies showed that all formulations released 
100% of the elemental calcium in simulated gastric fluid in less.  
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CHAPTER III 
AIM OF THE WORK 
 
Oral drug delivery system is most preferred  administration route due to 
its ease of administration and better patient compliance. Tablet is the most 
popular among all dosage forms existing today because of its convenience of 
self administration, compactness and easy manufacturing. One important 
drawback of such dosage forms is dysphagia, at difficulty in swallowing is 
common among  all age groups and more specific with pediatric and geriatric 
population.  
To overcome this weakness, developed a novel oral dosage of 
oraldispersible tablets are an innovative technology, which disperse rapidly in 
saliva, usually in a matter of seconds, without the need of water, providing 
optimal convenience to the patient as compared with conventional dosage 
forms.  
Lafutidine is a namely developed second generation of histamine H2 
receptor antagonist. It is used in the treatment of gastric ulcers, duodenal ulcers 
and gastric mucosal lesions associated with acute gastritis and acute 
exacerbation of chronic gastritis. Lafutidine has a receptors binding affinity 
which is 20 – 80 times higher than famotidine, ranitidine and cimetidine.  
Lafutidine is absorbed in the upper part of small intestine, reaches 
gastric cells via the systemic circulation and rapidly binds to gastric cells H2 – 
receptors, resulting in immediate inhibition of gastric acid secretion.  
The objective of this present study was to develop orodispersible tablets 
of lafutidine using superdisintegrants by simple cost effective direct 
compression technique which increased rate of dissolution may leads to 
increase in oral bio availability.  
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CHAPTER IV 
PLAN OF WORK 
 
1. Preparation of Standared calibration curve 
a. Determination of λ max 
b. Preparation calibration curve 
2. Pre-formulation (compatibility Studies) 
a. Infrared spectroscopic Studies 
b. Differential scanning colorimetric studies (DSC) 
3. Pre Compressional Evaluation of Powder Blend 
a. Angle of repose 
b. Bulk density 
c. Tapped density 
d. Carr’s index 
e. Hausner’s ratio 
4. Preparation of oral dispersible tablets 
Direct compression method 
5. Post compressional evaluation of oral dispersible tablets 
a. General appearance 
b. Thickness and diameter 
c. Hardness 
d. Weight variation 
e. Friability test 
f. Drug content 
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g. Wetting time 
h. Water absorption ratio 
i. In vitro disintegration test 
j. In vitro dissolution test 
 
6. Selection and evaluation of best  formulation 
a. Infra red spectroscopic studies of drug, physical mixture  
b. Differential scanning colorimetric (DSC) studies of drug and physical 
mixture 
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CHAPTER V 
MATERIALS AND EQUIPMENTS 
 
 
 
 
 
 
NO MATERIALS DISTRIBUTORS 
1 Lafutidine Niksan pharmaceutical,Gujarat, 
2 Sodium Carboxy Methyl 
Cellulose 
Central Drug House Pvt.,Ltd.,Delhi 
3 Cross Povidone Madras Pharmaceuticals - Chennai  
4 Scmc+Crosspovidone 
+Pregeatinized Starch 
Madras Pharmaceuticals - Chennai 
5 Pre gelatinished starch Apex laboratories pvt. Ltd., Chennai 
6 Microcrytline Cellulose Central drug pvt.ltd., delhi 
7 Mannitol Nice Chemicals Pvt. Ltd., Kerala 
8 Lactose Central drug house pvt. Ltd., delhi 
9 Magnesium strearate Central drug house pvt. Ltd., delhi 
10 Aspartame  Central drug house pvt. Ltd., delhi 
11 Lactose Central drug house pvt. Ltd., delhi 
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CHAPTER VI 
DRUG PROFILE 
Drug Name  : LAFUTIDINE 
STRUCTURE  : 
SOURCE  :  Synthetic 
DESCRIPTION  :  White to off-white colour powder 
CHEMICAL NAME  :  2-(Furan-2-ylmethylsulfinyl)-N-[(Z)-4- 
[4-(piperidin-1-ylmethyl) pyridin-2-yl] 
oxybut-2-enyl]acetamide 
MOLECULAR WEIGHT  :  431.55 g/mole 
MOLECULAR FORMULA : C22H29N3O4S 
MELTING POINT   : 96-104 0 C 
SOLUBILITY  :  Freely soluble in glacial acetic acid 
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BIOLOGICAL DISCRIPTION: 
Histamine H2 receptor antagonist. Inhibits distention-induced gastric 
acid secretion through an H2 receptor-independent mechanism. Shows 
antiulcer effects in vivo. Orallyactive. 
PURITY     :  > 99% 
STORAGE     :  Stored at room temperature 
HANDLING 
Wherever possible, you should prepare and use solutions on the same 
day. However, if you need to make up stock solutions in advance, we 
recommend that you store the solutionas Aliquots in tightly sealed vials at -
20°C. Generally, these will be useable for up to one month. Before use, and 
prior to opening the vial we recommend that you allow your product to 
equilibrate to room temperature for at least 1 hour. 
PHARMACOKINETIC DATA 
Protein binding    :  88% 
Half-life     :  1.92 ±0 .94 hour 
pH range     :  1- 4 
pka Value     :  3.9 
Oral bio availability   :  22-35% 
Nature     :  Hydrophobic. 
Identification    :  283 nm in UV spectrophotometer 
Route of administration   :  oral 
Dose     :  5mg, 10mg 
Dosage form    :  tablets 
Therapeutic categories   :  Second generation H2 – receptor  
Antagonist 
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Use      :  gastric ulcers, duodenal ulcers,  
stomach ulcers as well as wounds in 
the lining of the stomach associated 
with acute gastritis and acute 
exacerbation of chronic gastritis. 
PHARMACOKINETICS: 
Blood Concentration 
When 10mg of lafutidine is orally administered to normal adult males, 
fasting plasma concentration of unchanged drug changed. 
Metabolism and Excretion: 
Within 24 hours after perioral administration of lafutidine 10mg in 6 
normal adult males, the excretion rates of unchanged drug, metabolite M-4 
(oxidative elimination of piperidine ring), M-7 (oxidation of piperidine ring), and 
M-9 (sulfonylation) in the urine are10.9±1.5%,1.7±0.2% 7.5±.8% and 0.3±0.1% 
respectively. Total excretion rate in the urine isapproximately 20% of the given 
dosage. It has been reported that CYP3A4 is mainly (CYP 2D6 is partially) 
associated with the metabolism of lafutidine (in vitro). Unless reaching 3 mg/ml, 
no saturation of binding to protein is observed (Binding rate to human serum 
protein 88.0±1.2%) (in vitro). 
Mechanism of Action: 
Like other H2 receptor antagonists it prevents the secretion of gastric 
acid. It also activates calcitonin gene-related peptide, resulting in the stimulation 
of nitric oxide(NO) and regulation of gastric mucosal blood flow, increases 
somatisation levels also resulting in less gastric acid secretion, causes the 
stomach lining to generate more much inhibits neutrophil activation thus 
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preventing injury from inflammation, and blocks the attachment of Helicobacter 
pylori to gastric cells. 
INDICATIONS 
• Gastric ulcers, duodenal ulcers and stomach ulcers. 
• Gastric mucosal lesions (erosion, haemorrhage, redness or edema) 
associated with Acute gastritis and acute exacerbation of chronic 
gastritis. 
• Preanesthetic medication. 
ADVERSE REACTION: 
• Constipation 
• Diarrhoea 
• Nausea 
• Vomiting 
• Dizziness 
DOSAGE AND ADMINISTRATION 
• Gastric ulcers, duodenal ulcers and stomach ulcers 
For adults, the usual dosage is 10mg as lafutidine orally administered 
twice a day, once after breakfast and once after the evening meal or before 
sleeping. The dose may be adjusted according to the patient's age and 
symptoms. 
• Gastric mucosal lesions (erosion, haemorrhage, redness or edema) 
associated with acute gastritis and acute exacerbation of chronic 
gastritis 
For adults, the usual dosage is 10mg as lafutidine orally administered 
once a day, once after the evening meal or before sleeping. The dose may be 
adjusted according to the patient's age and symptoms. 
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• Preanesthetic Medication
For adults, the usual dosage is 10mg as lafutidine orally administered 
twice, once before sleeping on the day before operation and once 2 hours 
before introduction of anesthetic on the day of operation. 
Important Precaution 
Patients should be carefully observed during treatment, and the 
minimum required dose should be used according to symptoms. If response is 
not evident, other treatments should be implemented. Careful observation 
should be made for any changes inhaematological, hepatic or renal 
parameters, and for changes in other factors. 
Precautions Related to Dosage and Administration 
• In dialysis patients (not during dialysis), it is reported that their maximum
blood concentration of lafutidine increase twice as high as that of normal
adults.
• Therefore, the administration should be started carefully with lower
dosage.
CHAPTER VII 
EXCIPIENT PROFILE
CHAPTER VII                                                                 EXCIPIENT PROFILE  
 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 55 
 
 
 
CHAPTER VII 
EXCIPIENT PROFILE 
 
CROSPOVIDONE 
 
Synonyms: 
• Cross linked povidone 
• Kollido 
• Polyplasdone 
• Polyvinylpolypyrrolidone 
• 1-vinyl-2pyrrolidione homopolymer 
Chemical name : 
• 1-Ethynyl-2-pyrrolidinone homopolymer 
Chemical structure  
                                
Empirical formula 
• (C6H9NO)n 
Molecular Weight 
• >1,000 000 
Functional category 
• Tablet disintegrant 
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Application in Pharmaceutical formulation 
• Tablet disintegrant and dissolution agent 
• Solubility enhancer for poorly soluble drug 
Properties 
Acidity / Alkalinity  : pH = 5.0 – 8.0 (1% w/v aqueous slurry) 
Density   : 1.22 g/cm3 
Density (bulk)  : 0.3-0.4 g/cm3 
Density (tapped)  : 0.4-0.5 g/cm3 
Moisture content   : 60% 
Solubility   : Practically insoluble in water 
Description 
 Crospovidone is a white to creamy-white, finely divided, free flowing, 
practically tasteless, odourless or nearly odourless, hygroscopic powder. 
Stability and storage condition 
 Crospovidone is hygroscopic; it should be stored in an airtight container 
in a cool, dry place 
Incompatibilities 
 Crospovidone is compatible with most organic and inorganic 
pharmaceutical ingredients.  When exposed to a high water level, crospovidone 
may form molecular adduct with some materials. 
Handling precautions: 
Observe normal precautions appropriate to the circumstances and 
quantity of materials handled.  Eye protection, gloves, and a dust mask are 
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recommended (Handbook of Pharmaceutical excipients by Raymond C Rowe 
5th edition, 214-216, MalahahBinti Mohamed et al., 2012). 
 
Sodium Carboxy methyl Cellulose 
Synonyms :- sodium cellulose glycolate, Na CMC, CMC, cellulose gum, 
sodium CMC; INS NO.466  
Chemical Names :-  Sodium salt of carboxymethyl ether of Cellulose.  
C.A.S. number :- 9004-32-4  
Structural formula :-    
                          
Description:-  
white or slightly yellowish, almost odourless  Hygroscopic granules, 
powder or fine fibres Agent Characteristics  Identification  
Solubility (vol.4) :-  
Yield viscous colloidal solution with water ; insoluble    In ethanol PURITY  
Loss on drying(vol.4) :-  
Not more than 12% after drying (105, to constant                      
Weight).  
PH(vol.4):- 6.0-8.5(1 in 100 soln)  
Free glycolate :-  
Not more than  0.4% calculated as sodium glycolate on the dried basis  
Degree of substitution :- 
 Not less than 0.20 and not more than 1.50  
CHAPTER VII                                                                 EXCIPIENT PROFILE  
 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 58 
 
 
 
Pregelatinized Starch 
 
Synonyms 
• Compressible starch 
• Instastarch 
• Lycatab 
• Lycatab 
• Merigel 
• Pharma –Gel 
• Prejel 
• Sepistab ST 
• Starch 1500 
Chemical Name 
• Pregelatinized Starch 
Empirical Formula 
• (C6H10O5)n 
Molecular Weight 
• 300-1000 
Structural Formula  
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Functional category 
• Tablet capsule diluents 
• Capsule disinegrant 
• Tablet binder 
Applications 
• Binder 
• Diluent 
• Disintegrant 
• Lubricant 
Use Concentration % 
Diluent (hard gelatinecapsules) 5-75 
Tablet Binder (Direct compression) 5-20 
Tablet binder (wet granulation) 5-10 
Tablet disintegrants 5-10 
 
Description 
• Pregelatinized starch occurs as a moderately coarse to fine, white to off-
white coloured powder. It is odourless and has a slight characteristic 
taste. 
• Pregelatinized starch contains 5% of free amylase, 15% of free 
amylopectin, and 80% unmodified starch. 
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Properties 
Acidity / alkalinity : pH=4.5-7.0 for a 10% w/v aqueous  
dispersion 
Angle of repose : 40.7o 
Density (Bulk) : 0.586g/cm3 
Density (tapped) : 0.879g/cm3 
Density (true) : 1.516 g/cm3 
Flowability : 18-23 % (Compressibility index) 
Moisture content : Pregelatinized maize starch is hygroscopic 
Particle size distribution : 30-150μm 
Solubility   : Practically insoluble in organic solvents. 
Slightly soluble to soluble in cold water, 
depending upon the degree of 
pregelatinization. Cold-water-soluble matter 
for partially pregelatinized starch is      
10-20%. 
Specific surface area : 0.26m2/g 
Viscosity (dynamic)  : 8-10 cP 
Safety: 
• Pregelatinized starch are widely used in oral domage formulations.
Prefelatinized starch is generally regarded as a nontoxic and non irritant
excipient.  However, oral consumption of large amounts of
pregelatinized starch may be harmful.
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Handling precautions 
• Observe normal precautions appropriate to the circumstances and 
quantity of material handled.  Eye protection and a dust mask are 
recommended.  Excessive dust generation should be avoided to 
minimize the risks of explosions. 
Related substances: 
• Starch; starch, sterilizable maize 
Comments 
• A low moisture grade of pregelatinized starch, starch 1500 LM 
(Colorcon), containing less than 7% of water, specifically intended for 
use as a diluent in capsule formulations is commercially available. 
 
Magnesium Stearate 
       SYNONYMS 
      Magnesium Octadecanoate 
• Octadecanoic acid 
• Magnesium salt 
• Stearic acid 
• Magnesium salt 
Chemical name and CAS Registry Number 
• Octadecnoic acid magnesium salt [(557-04-0)] 
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Empirical formula and Molecular Weight 
• Magnesium stearate as a compound of a magnesium with a mixture of
solid organic acids that consists chiefly of variable proportions of
magnesium stearate and magnesium palmitatate.
• Magnesium stearate : C36H20Mg04 
• Magnesiumpalmitate : C32H62Mg04 
• Structural Formula : [CH3(CH2)16C00]Mg 
Functional category 
Tablet and capsule lubricant 
Applications in pharmaceutical formulations or technology 
• It is widely used in cosmetics, foods, and pharmaceutical formulations
• It is used as a lubricant in capsule and tablet manufacture at
concentrations 0.25% and 5.0% w/w
Description 
• Magnesium stearate is a very fine, light, white, precipitated or milled,
impalpable powder of powder of low density, having a faint odour of
stearic acid and a characteristic taste
• The powder is greasy to the touch and readily adheres to the skin
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Properties 
Crystalline forms   : High-purity magnesium stearate  
has been isolated as a trihydrate, 
adehydrate and anhydrate. 
Density (bulk)   : 1.059g/cm3 
Density (tapped)   : 0.286g/cm3 
Density (true)   : 1.092g/cm3 
Flash point    : 250oC 
Flow ability    : poorly flowing, cohesive powder 
Melting range   : 117-150oC 
(Commercial samples)  : 126-130oC (high purity  
      mangnesium stearate) 
Solubility    : practically insoluble in water;  
      slightly soluble in warm benzene  
      and warm ethanol (95%) 
Specific surface area  : 1.6-14.8m2/g 
Stability and Storage Condition 
• Magnesium stearate is stable and should be stored in a well closed 
contained in a cool, dry place. 
Incompatibilities 
• Incompatible with strong acids, alkalis, and iron salts 
• Magnesium stearate cannot be used containing asprin, some vitamins, 
and most alkaloidal salts. 
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Method of manufacture: 
• Magnesium stearate is prepared either by the interaction of aqueous 
solutions of magnesium chloride with sodium stearate or by the 
interaction of magnesium oxide, hydroxide, or carbonate with stearic 
acid at elevated temperatures. 
Safety 
• Magnesium stearate is widely used a pharmaceutical excipient and is 
generally regarded as being nontoxic as being nontoxic following oral 
following. 
• However, oral consumption of large quantities may produce a laxative 
effect or mucosal irritation. 
Handling precautions 
• Eye protection and gloves are recommended 
• Excessive inhalation of magnesium stearate dust may cause upper 
respiratory tract discomfort, coughing, and choking 
Related substances 
• Calcium stearate 
• Magnesium aluminium silicate 
• Stearic acid 
• Zinc stearate 
(Hand book of pharmaceutical excipients by Raymond C Rowe-5th editions, 
430-435) 
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MANNITOL 
Synonyms: 
• Cordycepic acid 
• Manna Sugar 
• D-mannite 
• Mannogrm 
• Pearlitol 
 
Chemical Name : 
D-Mannitol 
Empirical formula 
C6H1406 
Molecular Weight 
182.17 
Structural Formula 
                                  
Functional Category 
• Diluents 
• Sweetening agent 
• Tonicity agent 
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Application 
• It is used as diluent in tablet formulations (10-90% w/w). 
• It is used in pharmaceutical formulations and food products. 
• It is used in tablet applications include antacid preparations 
glyceryltrinitrite tablets, and vitamin preparation 
• It is used  as an excipient in the manufacture of chewable tablet 
formulations 
• Because of its negative heat of solution, sweetness, and mouth feel 
• In lyophilized preparation, mannitol (20-90% w/w) has been included  as 
a carrier to produce  a stiff, homogeneous cake that improves the 
appearance of the lyophilized plus in a vial 
• It is used in food applications as a bulking agent 
• Mannitol administered parentally is used as an osmotic diuretic; it is used 
in diagnostic agent for kidney function, as an adjunct in the treatment of 
acute renal failure. 
Description 
• Mannitol occurs as a white, odourless, crystalline powder, or free-flowing 
granules 
• It has a sweet taste, approximately as sweet glucose and half as sweet 
as sucrose, and imparts a cooling sensation in the mouth. 
Properties 
Density (bulk) 
• 0.430g/cm3 for powder 
• 0.7g/cm3 for granule 
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Density (tapped) 
• 0.734g/cm3 for powder 
• 0.8g/cm3 for granules 
Melting point 
166-168oC 
Flash point 
<150C 
Flow ability 
Powder is cohesive, granules are free flowing 
Specific surface area 
0.37-0.39m2/g 
Stability and storage conditions 
• Mannitol is stable in the dry state and in aqueous solutions 
• The bulk material should be stored in a well-closed contained in a cool, 
dry place 
Incompatibilities 
• Mannitol is incompatible with xylitol infusion and may form complex is 
with some metals such as a aluminium, copper, and iron 
• Mannitol solutions, 20 % w/v or stronger, may be salted out by potassium 
chloride or sodium chloride. 
• Mannitol is reducing sugar impurities have been implicated in the 
oxidative degradation of a peptide in alyophilized formation 
• Manitol was found to reduce the oral bio availability of cimetidine 
compared to sucrose 
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Handing precautions 
Mannitol mat be irritant to the eyes; eye protection is recommended 
Related substances 
Sorbitol 
Microcrystalline Cellulose 
Synonyms 
• Avicel pH
• Celex
• Celphere
• Ceolus KG
• Ethispheres
• Fibrocel
• Pharmacel
• Vivapur
Chemical name 
Cellulose 
Empirical Formula 
(C6H10O5) n 
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Structural formula :- 
                   
       
Molecular Weight 
36000 
Functional Category 
• Adsorbent 
• Suspending agent 
• Tablet and capsule diluents 
• Tablet disintegrant 
Application in Pharmaceutical Formulation 
• Microcrystalline cellulose is used as a binder / diluent in oral tablet and 
capsule formulations 
• Microcrystalline cellulose is used as a lubricant and disintegrant agent in 
tablet formulation 
• Microcrystalline cellulose is also used in cosmetics and food products 
Description 
• Microcrystalline cellulose is a white, odourless, tasteless, crystalline 
powder composed of porous particles 
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• Microcrystalline cellulose is hygroscopic 
Use Concentration (%) 
Adsorbent     - 20-90 
Anti-adherent   - 5-20  
Capsule binder/diluents  - 20-90 
Tablet disintegrants   - 5-15 
Tablet binder/diluents  - 20-90 
Pharmacopoeial Specifications 
pH     - 5.0-7.0 
Loss on drying   - 47.0 % 
Residue on ignition   - 40.05% 
Sulphated ash   - 40.1% 
Heavy metals   - 410 ppm 
Typical properties 
Density (tapped)   - 0.478g/cm3 
Density (True)   - 1.512-1.668g/cm3 
Flowability    - 1.41g/s for Emcocel 90M 
Melting point    - hars at 260-2708C. 
 
Stability and Storage Conditions 
Microcrystalline cellulose is a stable though hygroscopic material.  The 
bulk material should be stored in a well – closed container in a cool, dry place. 
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Incompatibilities 
Microcrystalline cellulose is incompatible with strong oxidizing agents 
Handling precautions 
Microcrystalline cellulose may be irritant to the eyes.  Gloves, eye 
protection, and adjust mask are recommended.  (Hand book of 
Pharmaceutical excipients by Raymond C Rowe – 5th edition 132-135).  
LACTOSE 
1)   Synonyms: 
• BP: Lactose monohydrate  
• JP: Lactose 
2) Empirical formula: 
C12 H22 O11 . H2O 
3)  Functional Formula: 
• Binding agent 
• Diluent for dry-powder inhalers 
• Tablet binder 
4) Application: 
• Lactose is widely used as a filler or diluents in tablets and 
capsules and to a more limited extent in lyophilized products and 
infant formulas. 
• Lactose is also used a diluents in dry-powder inhlation. 
CHAPTER VII                                                                 EXCIPIENT PROFILE  
 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 72 
 
 
 
• Direct compression grades of lactose are available as granulated 
/ agglomerated a- lactose monohydrate containing small amounts 
of anhydrous lactose. 
5) Typical properties: 
Compression pressure – 18.95-19.10 K N /cm2. 
6) Density: 
1.54 gm/cm3. 
    7)  Moisture content: 
        Lactose monohydrate contains approximately 5% w/w water of 
crytallization and normally has arrange of 4.5- 5.5%w/w water content. 
ASPARTAME 
Synonyms :-  
 Aspartyl Phenylaimine Methyl Ester ββ 
 Nutra sweet  
 Pat sweet  
 Canderel  
 Equal  
 Pal sweet diet   
Chemical Name :-  
N-A-L-Aspartyl-L-Phenylalaine 1 -methyl ester  
Emperical Formula :-  
C14 H18 N2O5    
CHAPTER VII                                                                 EXCIPIENT PROFILE  
 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 73 
 
 
 
Molecular Weight :-  
294.31 
Structural Formula :-          
 
Functional category :-  
Sweetering agent .  
Description :-  
Aspartame occurs as an off white, almost odourness, crystalline powder 
with an intensely sweet taste.  
Melting Point :-    
246-247c  
Solubility :-  
Slightly soluble in ethanol (95 %); sparingly soluble in water. At 20 c the 
solubility is 1% acidic pH, e.g., at ph2 and 20c solubility is 10% w/v.  
Solubility and Storage Conditions :-  
 Aspartame is stable in dry conditions. In the presence of moisthe, 
hydrolysis occurs to form the degradation. product L-aspartyl aearine & 3-
ben2yl-6-carboxy methyl-1,5 -diketopiperzine. A third-degradradation 
product is also known, β - L- aspartyl- L- phenyl alanine methyl ester.  
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 Aspartame degradation also occurs during prolonged heat treatment. 
Losse of aspartame may be minimized by using processes that employ 
high temperatures for a short time followed by rapid cooling.  
 The bulk material should be stored in a well-closed container in a cool, dry 
place.  
SAFETY :-    
Aspartame is widely used in oral pharmaceutical formulation beverages; 
and food products as an intense sweetens and is generally regarded as a non 
– toxic material. The WHO has set an acceptable daily intake for aspartame at 
to 40 mg/kg body – weight.  
Handling precautions :-  
Observe normal precautions appropriate to the circumstances & quality 
of material handled. Measures should be taken to minimize the potential for 
dust explosion. Eye protection is recommended.  
Application :-   
 Intense sweetening agent in beverage products, food products & table 
top sweetners, and in pharmaceutical preparations including tablets, 
powder mixs and vitamin preparations.  
 Therapeutically, aspartame has also been used in the treatment of sickle 
cell anemia. 
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TALC 
 
Synonyms 
• Altalc 
• Hydrous magnesium calcium silicate 
• Hydrous magnesium silicate 
Chemical Name 
• Talc 
• Purified talc 
• Talcum 
Empirical Formula 
• Talc is purified, hydrated, magnesium silicate 
• Mg6(si22oO5)4(OH)4 
• It may contain small, variable amounts silicate and iron 
Structural formula:- 
                                        
Functional category 
• Anticaking agent 
• Glidant 
• Diluent 
Applications in Pharmaceutical formulation 
• Talc is widely used in solid dosage formulation 
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• Diluents tablet and capsule (5.0-30.0) 
• It is widely used as a dissolution retardant in the development of 
controlled – release products 
• Talc is a novel powder coating for extended-release pellets, and as an 
adsorbent 
• It is used as a dusting powder  
• It is used to clarify liquids and is used in cosmetics and food products 
• It is used to baby powder 
 
Description 
Talc is a very fine, white to greyish-white, odourless, impalpable, 
unctuous, crystalline powder.  It adheres readily to the skin and is soft 
the touch and free from grittiness. 
Properties 
• Acidity / alkalinity  :  pH=7-10 for a 20% w/v aqueous  
        dispersion 
• Moisture content  :  Talc absorbs insignificant amounts of  
water at  25 C at relative humidity up to   
about 90% 
• Particle size distribution  : varies with the source and grade of  
                material.  Two typical grades are >/99%    
                 through a 44um (#325 mesh). 
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• Solubility   :   practically insoluble in diluents acids and  
                                alkalis, organic solvents, and water 
• Specific surface area :  2.41-2.42m2/ 
Stability and storage conditions 
• Talc is a stable material and may be sterilized by heating at 160oC for not 
less than 1 hour. 
• It may be also be sterilized by exposure to ethylene oxide or gamma 
irradiation 
• It may be also be sterilized by exposure to ethylene oxide or gamma 
irradiation 
• Talc should be stored in a well closed  container in a cool, dry place 
Incompatibilities 
Incompatible with quaternary ammonium compounds 
Handling precautions 
• Talc is irritant if inhaled and prolonged excessive exposure may cause 
pneumoconiosis 
• In the UK, the occupational exposure limit for talc is long-term (8 hour 
TWA). Eye protection, gloves, and a respirator are recommended 
Related substances 
• Bentonite 
• Magnesium aluminium silicate 
• Magnesium silicate 
• Magnesium trisilicate   
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CHAPTER VIII 
EXPRIMENTAL DETAILS 
 
I. CONSTRUCTION OF LAFUTIDINECALIBRAION CURVE WITH 
PHOPHATE BUFFER pH 6.8 
Preparation of pH 6.8 phosphate buffer solution 
  Take 50 ml of 0.2M Potassium Dihydrogen phosphate in a 200ml 
volumetric flask and add 22.4ml of 0.2M Sodium hydroxide solution, then the 
volume was made upto 200ml using distilled water.                                                                 
 Preparation of 0.2M potassium dihydrogen phosphate   
  27.218g of potassium dihydrogen phosphate was dissolved in distilled 
water and the volume was made up to 1000 using distilled water.                                   
Preparation of 0.2M sodium hydroxide 
 8g of sodium hydroxide was dissolved in distilled water and made up to 
 1000ml with distilled water. 
a.Determination of λ-max 
  100mg 0f Lafutidine lis taken in a 100ml volumetric flask and dissolved 
by using a small amount of phosphate buffer and made upto 100ml. This stock 
solution containing 1000µg/ml. This is further diluted into 10µg/ml. The resultant 
solution is scanned in the range of (200-400nm). 
b.Preparation of calibration curve 
From the above prepared stock solution, different concentration(5to 
50μg/ml) solutions are prepared. The absorbance of these solutions are 
measured at λmax (283)nm by UV- spectrophotometer. A standard curve is 
plotted using concentration on X-axis and the absorbance obtained on Y-axis. 
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II. COMPATABILITY STUDIES FOR DRUG AND EXCIPIENTS 
Compatibility studies are carried out to confirm whether there are no 
interactions existing between the drug and excipients. It gives information 
needed for selection of excipients with the drug for the formulation. 
Infrared spectroscopy and Differential scanning calorimetry studies are 
the two techniques used to check the compatibility between drug and 
polymers. 
 
Fourier Transform Infra-Red spectroscopic(FTIR) studies 
FT–IR spectra were recorded for lafutidine pure drug and pure drug with excipients 
using  IR- spectrophotometer. The samples were prepared in KBr dish and scanned 
over 4000 to 400 cm-1.  
 
 
 b.Differential scanning calorimetry (DSC) for best formulation: 
 
 Differential scanning calorimetry is used for screening. The 
specified samples is hermetically sealed aluminium pans at temperature 
20OC/min nitrogen werepurged at 50ml/min and 100ml/min through 
cooling unit (Himansu Chopra et al., 2012).  
            III. PRECOMPRESSION EVALUATION OF POWDER BLEND 
 The goals of the preformulation study are 
 
 To establish the necessary physicochemical characteristics of a new drug 
substance. 
 
 To determine its kinetics release rate profile. 
 
 To establish its compatibility with different excipients.  
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a. ANGLE OF REPOSE: 
 
The friction forces in a loose powder can be measured by the angle 
of repose (θ). It is an indicative of the flow properties of the powder. It is 
defined as the maximum angle possible between the surface of the pile 
of powder and the horizontal plane 
               
 
Where, 
 θ   -  angle of repose 
 h   -  height of pile in cm 
  r    -  radius of pile in cm 
 
  The powder mixture was allowed to flow through the funnel fixed to a 
stand at definite height (h). The angle of repose was then calculated by 
measuring the height and radius of the heap of powder formed. Care was 
taken to see that the powder particles slip and roll over each other through 
the sides of the funnel. Relationship between angle of repose and powder 
flow property (Debjit Bhowmik et al., 2009). 
 
 
TABLE 1: LIMITS FOR ANGLE OF REPOSE 
 
ANGLE OF REPOSE POWDER FLOW 
< 25o EXCELLENT 
25-30o GOOD 
30-40o PASSABLE 
>40o VERY POOR 
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b. Bulk Density (Db):
It is the ratio of total mass of powder to the bulk volume of powder. It 
was measured by pouring the weighed powder (passed through standard 
sieve # 20) into a measuring cylinder and initial weight was noted. This initial 
volume is called the bulk volume. From this the bulk density is calculated 
according to the formula mentioned below. It is expressed in g/ml and is 
given by (Debjit Bhowmik et al., 2009). 
Where, 
M  - Mass of the Powder 
Vb -  Bulk volume of the powder 
c. TAPPED DENSITY:
It is the ratio of total mass of the powder to the tapped volume of the 
powder. Volume was measured by tapping the powder for 750 times and 
the tapped volume were noted if the difference between these two volumes 
is less than 2%. If it is more than 2%, then tapping is continued for 1250 
times and tapped volume was noted. Tapping was continued until the 
difference between successive volumes is less than 2 % (in a bulk density 
apparatus). It is expressed in g/ml and is given by (Debjit Bhowmik et al., 
2009) 
Where, 
M - mass of powder 
Vt -  tapped volume of the powder. 
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D. PERCENTAGE OF COMPRESSIBILITY (OR) CARR’S INDEX: 
It indicates powder flow properties. It is expressed 
in percentage and is given as the Following 
 
 
  
TABLE 2:  
RELATIONSHIP BETWEEN % COMPRESSIBILITY AND FLOW ABILITY 
 
% 
Compressibility 
 
Flow ability 
5 – 12 Excellent 
12 – 16 Good 
18 – 21 Fair passable 
23 – 35 Poor 
33 – 38 Very poor 
< 40 Very very poor 
 
e.Hausner ratio: 
 
Hausner ratio is an indirect index of ease of powder flow. It Is calculated by the  
following formula (Debjit Bhowmik et al., 2009). 
 
 
Lower hausner ratio (<1.25) indicates better flow properties than higher 
ones (>1.25). 
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TABLE 3: 
Relationship between flow characters and Hausner’s ratio 
 
Flow characters Hausner’s ratio 
Excellent 1.00 – 1.11 
Good 1.1 – 1.18 
Fair 1.19 – 1.25 
Passable 1.26 – 1.34 
Poor 1.35 – 1.45 
Very poor 1.46 – 1.59 
Very very poor >1.60 
 
 
III. FORMULATION  OF LAFUTIDINE  ORO-DISPERSIBLE TABLETS 
 Using different superdisintegrants 
 Synthetic superdisintegrants 
-Sodium Carboxy methyl cellulose 
-Crospovidone 
 Natural superdisintegrants 
Pregelatinized starch  
PREPARATION OF ORODISPERSIBLE TABLETS OF LAFUTIDINE   
              Lafutidine is mixed with super disintegrate crospovidone, sodium 
carboxy methyl cellulose, pregelatinize starch manitol used as mouth feel 
enhancer,Microcrysstalline cellulose as diluted and binder, lactose as diluents, 
aspartame as sweetner, talc as glidant and Magnesium stearte as lubricant. All 
the ingredients were passed through 60 mesh Separately, weighed and mixed 
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in geometrical order in to motor and pestle for 10 min.The blend thus obtained 
was directly compressed on 12 station rotary punching  machine to get 10 mg 
of lafutidine.Each tablet weighing of 200 mg. 
     F1,F2,F3 formulation are prepared by using sodium carboxy methyl 
cellulose super disintegrants in 2%,3%,4% respectively.F4,F5,F6 frmulation 
prepared by using cros povidone superdisintegrant in 2%,3%,4% 
respectively.F7,F8,F9 formulation prepared by using pregelatinized starch 
superdisintegrants in 2%,3%,4% respectively.  
F10.F11,F12 formulation prepared by using combination of SEMC 
,pregelatinized starch, cros povidone in 3%,4.5%,12% respectively. 
By direct compression 
All the formulation components other than lubricants and Glidant were 
accurately weighed, passed through 60-mesh sieve and mixed well for 30 
min. Talc and magnesium stearate were passed through 80-mesh sieve, 
mixed with above blend for 10 min and resultant blend was directly 
compressed into tablets. The amount of all tablet components other than 
superdisintegrant and diluents were kept constant. Round flat tablets of 200 
mg weight and 8 mm diameter were prepared using 12 station B/D tolling 
compression machine  by direct compression technique.(kalyankar et al., 
2015). 
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IV. EVALUATION OF POST COMPRESSION PARAMETERS OF 
LAFUTIDINE ORO-DISPERSIBLE TABLETS  
a.General appearance 
The general appearance of a tablet, its visual identity and over all 
“elegance” is essential for consumer acceptance. Tablet’s size, shape, 
colour, surface texture, physical flaws and consistency are noted. 
B. TABLET THICKNESS & DIAMETER: 
Tablet thickness is an important characteristic in reproducing 
appearance. Tablet thickness and diameter can be measured using a 
simple procedure. 3 tablets were taken and their thickness and diameter 
was measured using digital Vernier calipers. (Amit Modi et al., 2012). 
C.TABLET HARDNESS: 
 
Hardness of tablet is defined as the force applied across the diameter 
of the tablet in the order to break the tablet. The resistance of the tablet to 
chipping, abrasion or breakage under condition of storage transformation 
and handling before usage depends on its hardness. Hardness of the tablet 
of each formulation was determined using Pfizer hardness tester (Mukesh 
et al., 2008). 
d. UNIFORMITY OF WEIGHT: 
 
I.P. procedure for uniformity of weight was followed, twenty tablets were 
taken and their weight was determined individually and collectively on a 
digital weighing balance. The average weight of one tablet was determined 
from the collective weight. The weight variation test would be a satisfactory 
method of determining the drug content uniformity (Mukesh et al., 2008). 
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TABLE 3: I. 
P. SPECIFICATION FOR UNIFORMITY OF WEIGHT 
AVERAGE WEIGHT OF TABLET % DEVIATION 
80mg or Less ± 10 
More than 80mg but less than 250mg ± 7.5 
250mg or more ± 5 
 
e.Friability 
It is measure of mechanical strength of tablets. Roche Friabilator was 
used to determine the friability by following procedure. A preweighed tablet 
was placed in the Friabilator. Friabilator consist of a plastic chamber that 
revolves at 25 rpm, dropping those tablets at a distance of 6 inches with each 
revolution. The tablets were rotated in the Friabilator for at least 4 minutes. 
At the end of test tablets they were disused and reweighed, the loss in the 
weight of tablet is the measure of friability and is expressed in percentage as 
(Mukesh et al., 2008) 
          % FRIABILITY = LOSS IN WEIGHT / INITIAL WEIGHT × 100 
  
f.Uniformity of drug content: 
  Randomly Ten tablets of formulation were weighed and crushed in 
mortar and powder equivalent to lafutidine 200mg of lafutidine was weighed 
and dissolved in phosphate buffer pH 6.8, the volume was made up to 100ml. 
From the stock solution 10ml sample was withdrawn and diluted to 100ml with 
phosphate buffer Ph 6.8. The absorbance was measured at wavelength 283 
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nm using UV-Visible spectrophotometer. Content uniformity was calculated 
using formula (Amit Modi et al., 2012). 
g.In vitro dissolution studies
Dissolution rate was studied by using USP type –II apparatus 
(dissolution test apparatus at 50 rpm) using 500 ml phosphate buffer pH 6.8 
as dissolution medium. Temperature of the dissolution medium was 
maintained at 37 ± 0.50C, sample was withdrawn at every 5 min interval and 
diluted suitably and the absorbance of solution was measured by UV 
spectrophotometer method at 283nm and concentration of the drug is 
determined from the standard calibration. 
h.In vitro release studies details:
Apparatus used        :    USPXXIII dissolution test apparatus  
Dissolution medium                   :     phosphate buffer pH 6.8           
Dissolution medium volume      :    500ml 
Temperature              :    37 ± 0.50C 
Speed of paddle                         :    50rpm 
Sampling intervals         :    5 min 
Sample withdraw          :    10ml 
Absorbance measured :    231nm 
i. In vitro disintegration time
The test was carried out on 6 tablets using the apparatus specified in IP 
2010 distilled water at 37OC ± 2OC was used as a disintegration medium and 
the time in seconds taken for the entire tablet to disintegrate completely 
(Shallesh Sharma et al., 2008). 
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DISINTEGRATION TIME 
 Uncoated tablets : 5 -30 minutes 
 Coated tablets : 1- 2 hours 
 Fast dissolving tablets : less than 3 minutes (European
pharmacopeia)
J.WATER ABSORPTION RATIO 
A piece of tissue paper folded twice was placed in a small Petri dish 
containing 6 ml of water. A tablet was put on the paper and time required for 
complete wetting was measured. Three tablets from each formulation were 
prepared and standard deviation was also determined (Venkateswara et al., 
2014). 
 The wetted tablet was then weighed. Water absorption ratio R, was 
determined using equation- 
R = 100×WA-WB /WB 
Where, 
Wb   =  weight of the tablet before water absorption 
Wa   =  weight of the tablets after water absorption 
K. WETTING TIME 
A piece of tissue paper folded twice was placed in a small petri dish 
containing 6 ml of water or eosin dye and a tablet was put on the paper. The 
time for complete wetting was measured. Three trials for each batch were 
performed and standard deviation was also determined (venkateswara et 
al., 2014).  
BEST FORMULATION SELECTION 
The selection of best formulation is done based on rate of 
Lafutidine release from the in vitro dissolution studied.
CHAPTER iX 
RESULT AND DISCUSSION
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CHAPTER IX 
RESULTS AND DISCUSSION 
I. PREPARATION OF STANDARDCALIBRATION CURVE FOR         
LAFUTIDINE 
Determination of λ-max 
The absorption maximum (λmax 283 nm) of the Lafutidine was 
estimated by scanning the drug solution (10µg/ml) between 200-400 nm 
regions on UV spectrophotometer. The obtained spectrum showed that 
the absorption maximum (λmax) was 283 nm for the Lafutidine. FIG.1 
Calibration of Lafutidine in phosphate buffer pH 6.8 
The Standard Calibration curves of Lafutidine were prepared using 
phosphate buffer pH 6.8. The absorbance were measured at λmax of 283nm. 
The correlation coefficient was found to be 0.9994. Lafutidine obeys the 
beer’s law within the concentration range of (5-50µg/ml). Calibration plot of 
lafutidine in phosphate buffer pH 6.8 was shown in FIG.2 and Table 1. 
II. COMPATABILTY STUDIES FOR DRUG AND EXCIPIENTS
Fourier Transform Infra-Red Spectroscopic (FT-IR) Studies 
FT-IR spectrum of the pure drug and mixture of pure drug and 
excipients used in the formulation were recorded. The spectra of pure 
Lafutidine showed characteristic peaks at 3282 cm-1, 3118cm-1, 1656 cm1, 
1608cm-1. All the above peaks were also observed in the spectra of 
mixture of lafutidine and excipients with slight deviations. This indicating 
that the drug is stable and there is no drug-excipient interaction (Bhaskar 
Umarji et al., 2012) Fig. 3A, 3B, 3C, 3D,3E, 3F, 3G, 3H and  3I  . 
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III. PREFORMULATION EVALUATION OF POWDER BLEND
The prepared tablets were evaluated on various parameters such as 
thickness and diameter, hardness, weight variation, friability, uniformity content, 
wetting time, water absorption ratio, In-vitro disintegration time and In-vitro 
dissolution test. The results were summarized in Table 3. 
Angle of repose 
The angle of repose was used to determine the flow properties of powder 
blend. The angle of repose of the formulations ranged from24˚05’ to 30˚ 02’.The 
results indicated that the formulations with synthetic superdisintegrants  
exhibited good flow properties whereas the natural superdisintegrants had a 
passable flow property. The results of angle of repose for all the formulations 
were shown in Table 3 and FIG. 6. 
Bulk density 
The bulk density is used as an index of the ability of the powder to flow. 
The bulk density of the formulations was in the range of 0.684 – 0.711 g/ml. 
The values of bulk density showed that the blend was not tightly packed and 
indicated good flow properties for synthetic super disintegrants  and passable 
for natural super disintegrants diluents. The results of bulk density for all the 
formulations were shown in Table 3 and FIG. 7. 
Tapped density 
The tapped density was used to access the free flowing properties of 
powder blend. The tapped density of the formulations were in the range of 0.77-
0.87 g/cm3.The results indicated that the blends of the formulation had good
flow properties for synthetic superdisintegrants and passable for natural 
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superdisintegrants. The results of tapped density for all the formulations were 
shown in Table 3 and FIG. 8. 
Carr’s compressibility index 
The Carr’s compressibility index was used to access the free flowing 
properties of powder blend. The compressibility index of all the formulations 
ranged from 16.9 –23.17%. The value below 16% has a good flow property and 
good propensity of compression. The results of compressibility for all 
formulations were shown in Table 3 and FIG. 9. 
Hausner’s ratio 
The Hausner’s ratio was an indirect index of ease of powder flow. The 
Hausner’s  ratio of all the formulations ranged from 1.11-1.25. This indicates better 
flow property of blend. The results of Hausner’s ratio for all the formulations were 
shown in Table 3 and FIG.10. 
IV. FORMULATION OF LAFUTIDINE ORODISPERSIBLE TABLETS
The orodispersible tablets of Lafutidine was prepared by direct 
compression method using synthetic superdisintegrants (sodium carboxy 
methyl cellulose and crospovidone) and natural superdisintegrants (pre 
gelatinized starch). The compositions of the different formulation were given 
in Table 2A and 2B. Twelve Formulations (F1 to F12) were prepared as per 
formula designed. All the tablets were white color and round in shape having 
6 mm diameter. 
V. POST COPMRESSION EVALUATION 
a. General appearance
The tablets were white coloured and round shaped. All tablets were 
elegant in appearance. 
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b. Thickness and diameter
The thickness and diameter of the formulations were used to 
determine the uniformity of size and shape of the tablets. From the results it 
was found that the thickness of the tablet in all formulation was 3.3-3.4mm 
and the diameter of the tablet in all formulation was 6mm.The results 
indicated that all the formulations had uniform size and shape. The results 
were shown in Table 4A. 
c. Hardness
The hardness of the tablets was used to determine the resistance 
capacity of the tablets to chipping, abrasion or breakage under conditions of 
storage, transportation and handling before usage. The hardness of the 
tablets of all the formulations was found to be in the range of 3.16-3.76 
kg/cm2. The result indicated that all the tablets had a good mechanical
strength. The results of the hardness for all the formulations were shown in 
Table 4A. 
d. Weight variation test
The weight variation test was used to ensure the uniformity of the tablet 
in all formulations. The weight of all the tablets from each formulation was in 
the range from 193.4 mg to 200.70 mg. It was found all the tablets passed 
weight variation test, as the percentage weight variation was within the 
acceptable limits of ±7.5%. The results were shown in Table 4A. 
e. Friability test
Friability test was measured to ensure the mechanical strength of tablet. 
The results showed that the friability of all the formulation ranged from 0.48% 
to 0.65%. Friability of all the formulation was lesser than 1 % which indicated 
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the tablets had a good mechanical resistance. The results were shown in    
Table 4A. 
f. Uniformity of drug content
The uniformity content test was used to determine the uniform amount of
active ingredient present in all formulations. The drug content in the content 
uniformity of all the formulations was found to be in the range of 98.2 % - 
99.70%. The results indicated all the formulations were within the acceptable 
limits as per USP limits. The results were shown in Table 4A. 
g. In vitro drug release study
The dissolution profile range in 30 minutes was 88.13% to 97.79% 
(Table 5A and 5B). The drug release was found to be comparatively less in         
formulation containing natural superdisintegrant (pre gelatinized starch).
The maximum dissolution drug release rate was observed with the
formulation containing scmc + crospovidone + pregelatinizedstarch as a      
synthetic superdisintegrants.(FIG. 12A, 12B, 12C and 12D) 
The formulation containing scmc +crospovidone+pregelatinized starch 
(3%+ 4.5%+ 12%)  was to show dissolution in 30minutes of dissolution       study 
produced 97.79% which compiled with WHO guideline. Many factors       
contributed for faster drug release rate such as rapid disintegration and       
increased wettability. Among the 12 formulations the formulation 12 (F12)  was 
selected, as a best formulation because of its desirable character of        low 
disintegration time, highest drug release, high water absorption rate         and 
short wetting time.  
h. In vitro disintegration time
The in-vitro disintegration time was determined by disintegration test 
apparatus. The results were shown in Table 4B. Formulations F1, F2, F3, 
F4, F5, F6, F7, F8, F9, F10, F11 and F12 showed the disintegration time 
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65.0, 50.06, 30.0, 70.6, 45.3, 32.3, 50.0, 40.0, 25.0, 25.6, 20.6 and 18.0  
seconds respectively. It was observed that Formulation F12 containing scmc 
+crospovidone+pre gelatinized starch (3% + 4.5% + 12%) disintegrated 
rapidly in a short time (18.0 seconds). The results of disintegration of all the 
tablets were found to be lesser than 180 seconds. So all the formulation 
satisfied the criteria of fast dissolving tablets. 
i. Water absorption ratio
The water absorption ratio test was used to ensure the capacity of the 
superdisintegrant and the diluent to absorb the water. The results of water 
absorption ratio of all the formulation were shown in Table 4B. 
Formulations F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11 and F12 
showed the water absorption ratio 75.18%, 71.28 %, 75.18%, 16.58%, 78.53, 
85.72%, 71.53%, 71.53%, 96.64%, 81.65%, 94.11%, and 98.78% respectively. 
The results showed that as concentration of superdisintegrant increased water 
absorption ratio was also increased. Formulation F12 containing scmc 
+crospovidone+pre gelatinized starch (3% + 4.5% + 12%) as showed highest 
water absorption ratio (98.78%) when compared to other formulations. 
The reason for high water absorption ratio for F12 formulation containing 
scmc +crospovidone + pre gelatinized starch quickly wicks water in to the tablet 
to generate volume expansion. scmc + crospovidone + pre gelatinized starch 
uses combination of swelling and wicking. 
j. Wetting time
Wetting time of the tablet was used to assess the capacity of the 
tablets to disintegrate by swelling in water. All the formulations showed 
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quick wetting, this may be due to ability to swelling and also capacity of 
absorption of water. The results of wetting time of all the formulations were 
shown in Table 4B. 
The formulationsF1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11  
and  F12 showed the wetting time, 68.17, 62.0, 69.6, 72.6, 73.0, 70.9, 
56.0, 65.9, 54.0, 56.0, 61.2 and 69.1seconds respectively. The results 
indicated that the concentration of superdisintegrant influenced the 
wetting time. Formulation F12 containing scmc +crospovidone+pre 
gelatinized starch (3% + 4.5% + 12%) showed lesser wetting time than 
other formulations. 
This may be due to fact that superdisintegrant – scmc 
+crospovidone+pre gelatinized starch performed its action by the 
combination of wicking and swelling action. Formulation F12 showed 
shorter wetting time. (Debjit Bhowmik et al., 2009). 
VI. COMPARISION OF DISSOLUTION DATA OF LAFUTIDINE TABLETS
CONTAINING DIFFERENT SUPERDISINTEGRANTS
The tablets prepared with scmc +crospovidone+pre gelatinized 
starch showed maximum drug release of 97.79% whereas tablets 
containing sodium mannitol diluent showed maximum drug release of 
92.38%, 94.05% and 97.79% respectively. 
VII. SELECTION OF BEST FORMULATION
Among twelve formulations, the best was selected on the basis of
lowest disintegration time, rapid drug release profile, higher water 
absorption ratio, short wetting time. Formulation F12 showed lowest 
disintegration time of 18.0 seconds, faster drug release rate of 97.79 %in 
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30 minutes, comparatively high water absorption ratio of 98.78% and short 
wetting time of 69.1 seconds. In these parameter would drive the F12 
formulation as a best formulation. 
VIII. EVALUATION OF SELECTED FORMULATION
a.Differential Scanning Calorimetry (DSC) Studies
Any possible drug polymer interaction can be studied by thermal 
analysis. The DSC thermogram of lafutidine exhibited an sharp endothermic 
peak at at 104.18oC, which corresponding to its melting temperature. The 
thermogram of the final best formulation of lafutidine with other excipients 
show the existence of drug endothermic peak within the range which 
indicated the absence of interaction between the drug and other excipients. 
The DSC thermogram of pure drug and the final best formulation is 
presented in FIG. 5A and 5B . 
b. Fourier Transform Infra-Red (FT-IR) Spectroscopic studies
Infrared spectra of the lafutidine orodispersible tablets showed major 
peaks at 3282 cm-1, 3118cm-1, 1656 cm-1, 1608cm-1 indicated that there was 
no interaction between the drug and the final formulation throughout the 
preparation of orodispersible tablets. The result was shown in FIG. 3J. 
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TABLE- 1 CALIBRATION OF LAFUTIDINE  USING PHOSPHATE            
BUFFER PH6.8
S.NO CONCENTRATION 
(µg/ml)   
ABSORBANCE 
1 5 0.0843 ± 0.0019 
2 10 0.1606 ± 0.0028 
3 15 0.2427 ± 0.0044 
4 20 0.3251 ± 0.0186 
5 25 0.3982 ± 0.0104 
6 30 0.4756 ± 0.0093 
7 35 0.5542 ± 0.0135 
8 40 0.6311 ± 0.0061 
9 45 0.7123 ± 0.0168 
10 50 0.7894 ± 0.0214 
   Regression  – 0.9994 ± 0.0001667 
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TABLE- 2  COMPOSITION OF ORODISPERSIBLE TABLE OF LAFUTIDINE 
S.NO Ingredients(mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
1 Lafutidine 10 10 10 10 10 10 10 10 10 10 10 10 
2 Sodium carboxy methyl cellulose 5 10 15 - - - - - - - - - 
3 Crospovidone  - - - 5 10 15 - - - - - - 
4 Pregelatinzied Starch - - - - - - 5 10 15 - - - 
5 Scmc + Cross + Press - - - - - - - - - 10 15 20 
6 Microcrystalline cellulose 90 90 90 90 90 90 90 90 90 90 90 90 
7 Lactose 61 56 51 61 56 51 61 56 51 56 51 46 
8 Mannitol 20 20 20 20 20 20 20 20 20 20 20 20 
9 Aspartame 10 10 10 10 10 10 10 10 10 10 10 10 
10 Talc 2 2 2 2 2 2 2 2 2 2 2 2 
11 Magnesium stearate 2 2 2 2 2 2 2 2 2 2 2 2 
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TABLE 3 -EVALUATION OF MIXED POWDER BLEND OF LAFUTIDINE 
Formulation 
Code
Angle of repose 
(°) ± SD*
Bulk density 
(g/ml) ± SD*
Tapped density  
(g/ml) ± SD*
Carrs index 
(%) ± SD*
Hausner’s ratio 
± SD*
Drug Content 
(%) ± SD* 
F1 28.1 ± 0.09 0.704 ± 0.07 0.775 ± 0.19 19.0 ±0.01 1.10 ± 0.02 0.775 ± 0.19 
F2 26.3 ± 0.12 0.684 ± 0.18 0.833 ± 0.31 17.9 ± 0.08 1.21 ± 0.03 0.833 ± 0.31 
F3 27.34 ± 0.24 0.693 ± 0.65 0.806 ± 0.23 16.9 ± 0.03 1.16 ± 0.01 0.806 ± 0.23 
F4 26.9 ± 0.10 0.687 ± 0.35 0.840 ± 0.24 18.17± 0.01 1.22  ± 0.03 0.840 ± 0.24 
F5 30.0 ± 0.02 0.707 ± 0.17 0.848 ± 0.09 16.66 ± 0.54 1.20  ± 0.03 0.848 ± 0.09 
F6 28.0 ± 0.03 0.685 ± 0.20 0.824 ± 0.28 21.5 ± 0.02 1.20 ± 0.01 0.824 ± 0.28 
F7 24.05 ± 0.39 0.711 ± 0.12 0.790 ± 0.19 20.8 ± 0.02 1.11  ± 0.02 0.790 ± 0.19 
F8 27.37 ± 0.24 0.70 ± 0.16 0.875 ± 0.41 23.1 ± 0.0.01 1.25 ± 0.01 0.875 ± 0.41 
F9 25.75 ± 0.12 0.697 ± 0.35 0.776 ± 0.29 23.7 ± 0.01 1.11  ±  0.00 0.776 ± 0.29 
F10 29.40 ± 0.41 0.70 ± 0.16 0.875 ± 0.41 22.8 ± 0.01 1.25  ±  0.02 0.875 ± 0.41 
F11 28.61 ± 0.10 0.687 ± 0.35 0.840 ± 0.24 18.7 ± 0.02 1.22  ±  0.03 0.840 ± 0.24 
F12 27.34 ± 0.29 0.693 ± 0.65 0.806 ± 0.23 16.9 ± 0.03 1.16  ± 0.01 0.806 ± 0.23 
CHAPTER 10                  TABLES  AND FIGURES  
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 100 
TABLE 4 - EVALUATION OF ORODISPERSIBLE TABLE OF LAFUTIDINE 
Formulation 
Code 
 General 
appearance  
Thickness  
mm 
Hardness 
kg/m2 
Average weight 
(mg)  ± 7.5  
Friability 
(%) 
Content 
uniformity 
Disintegration 
Time (sec) 
Water 
absorption 
ratio (%) 
Wetting 
time (sec) 
F1 white 3.56  ± 0.01 3.26 ±0.15 200.0 ± 0.41 0.55 ± 0.51 99.55 ± 0.86 65.0 ±1.63 75.18 ± 0.50 68.17 ± 0.27 
F2 white 3.43± 0.01 3.43 ± 0.05 200.7 ±0.62 0.48 ±0.06 97.15 ±0.95 50.6 ± 0.47 71.28 ± 1.69 62.0 ±0.81 
F3 white 3.42 ± 0.01 3.16 ±0.40 199.56 ± 0.49 0.55 ±0.02 89.06 ±0.75 30.0 ± 1.63 75.18 ± 1.29 69.6 ± 1.2 
F4 white 3.32 ±0.11 3.50 ±0.40 199.2 ± 0.18 0.65 ±0.03 87.14 ±0.95 70.6 ± 2.3 60.58 ± 1.11 72.6 ± 1.2 
F5 white 3.39±0.05 3.50 ±0.40 204.6 ±0.52 0.53 ±0.16 85.78 ±0.78  45.3 ± 1.70 78.53 ± 0.84 73.0 ± 0.8 
F6 white 3.32 ±0.00 3.00 ±0.40 201.3 ± 0.63 0.60 ± 0.08 88.62 ±0.40 32.3 ±1.70 85.72 ± 0.43 70.9 ± 0.55 
F7 white 3.42 ±0.00 3.66 ±0.84 202.6 ±0.58 0.57 ± 0.16  90.24 ±0.31 50.0 ± 1.63 71.53 ± 0.43 56.0 ± 1.6 
F8 white 3.32 ±0.00 3.33 ±0.23 199.1 ±0.53 0.59 ±0.14 88.71 ± 0.31 40.0 ± 1.33 71.53 ± 1.07 65.9 ± 0.4 
F9 white 3.39 ±0.00 3.66 ± 0.84 193.4 ±0.37 0.59 ± 0.01 88.94 ±0.85 25.0 ± 1.47 96.64 ± 1.89 54.0±1.6 
F10 white 3.32 ±0.00 3.66 ± 0.84 198.2 ± 0.19 0.52 ±0.01 99.98 ±0.72 25.6 ± 0.21 81.65 ± 1.78 56.0 ±1.4 
F11 white 3.43 ± 0.17 3.76 ± 0.40 199.0 ±0.08 0.53 ±0.068 99.17 ± 0.06 20.6 ± 0.96 94.11 ± 1.89 61.2 ± 0.23 
F12 white 3.43 ± 0.05 3.16 ± 0.62 199.2 ± 0.48 0.55 ±0.02 99.94 ± 0.06 18.0 ± 0.4 98.78 ± 1.89 69.1 ± 1.2 
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Table 5 A - VITRO RELEASE PROFILE OF LUFUTIDINE ORODISPERSIBLE TABLETS 
Time in 
Minutes 
Cumulative Percentage drug release ± SD* 
F1 F2 F3 F4 F5 F6 
5 41.75 ± 0.29 30.43 ± 0.86 32.35 ± 0.87 33.40 ± 0.29 26.42 ± 0.32 17.68 ± 1.04 
10 54.45 ± 0.22 48.66 ± 1.49 59.58 ± 1.49 58.70 ± 0.18 37.85 ± 0.42 32.78 ± 0.45 
15 62.49 ± 0.96 60.76 ± 2.16 65.28 ± 2.47 67.13 ± 0.41 50.58 ± 0.51 53.47 ± 1.13 
20 79.35 ± 2.77 76.84 ± 2.72 76.76 ± 3.32 78.49 ± 0.29 67.44 ± 1.81 64.89 ± 1.19 
25 77.39 ± 2.09 83.66 ± 1.53 85.62 ± 2.76 87.21 ± 0.44 72.84 ± 0.41 72.84 ± 0.41 
30 87.13 ± 1.05 86.51 ± 0.52 94.44 ± 1.82 94.05 ± 0.47 90.20 ± 1.50 86.20 ± 1.50 
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Table  5 B - VITRO RELEASE PROFILE OF LUFUTIDINE ORODISPERSIBLE TABLETS 
Time in Minutes Cumulative Percentage drug release ± SD* 
F7 F8 F9 F10 F11 F12 
5 17.90 ± 1.04 33.40 ± 0.29 12.93 ± 0.23 31.65 ± 0.20 33.40  ± 40 59.22 ± 1.19 
10 25.82 ± 0.45 58.70 ± 0.18 26.43 ± 0.54 51.42 ± 0.46 58.70 ± 0.18 80.31 ± 1.18 
15 33.24 ± 1.13 67.13 ± 0.41 40.61 ± 0.94 65.89 ± 1.19 67.13 ± 0.41 89.67 ± 0.34 
20 43.89 ± 1.19 78.49 ± 0.29 55.54 ± 1.47 76.21 ± 1.50 78.49 ±0.29 91.12 ± 0.33 
25 58.70 ± 0.41 87.21 ± 0.44 71.42 ± 4.61 83.21 ± 1.42 87.49 ± 0.44 95.49 ±1.41 
30 88.87 ± 1.50 94.05 ± 0.47 88.55 ± 1.19 92.38 ± 0.45 94.05 ± 0.47 97.79 ± 0.88 
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TABLE- 1 CALIBRATION OF LAFUTIDINE  USING PHOSPHATE            
BUFFER PH6.8
S.NO CONCENTRATION 
(µg/ml)   
ABSORBANCE 
1 5 0.0843 ± 0.0019 
2 10 0.1606 ± 0.0028 
3 15 0.2427 ± 0.0044 
4 20 0.3251 ± 0.0186 
5 25 0.3982 ± 0.0104 
6 30 0.4756 ± 0.0093 
7 35 0.5542 ± 0.0135 
8 40 0.6311 ± 0.0061 
9 45 0.7123 ± 0.0168 
10 50 0.7894 ± 0.0214 
   Regression  – 0.9994 ± 0.0001667 
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TABLE- 2  COMPOSITION OF ORODISPERSIBLE TABLE OF LAFUTIDINE 
S.NO Ingredients(mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
1 Lafutidine 10 10 10 10 10 10 10 10 10 10 10 10 
2 Sodium carboxy methyl cellulose 5 10 15 - - - - - - - - - 
3 Crospovidone  - - - 5 10 15 - - - - - - 
4 Pregelatinzied Starch - - - - - - 5 10 15 - - - 
5 Scmc + Cross + Press - - - - - - - - - 10 15 20 
6 Microcrystalline cellulose 90 90 90 90 90 90 90 90 90 90 90 90 
7 Lactose 61 56 51 61 56 51 61 56 51 56 51 46 
8 Mannitol 20 20 20 20 20 20 20 20 20 20 20 20 
9 Aspartame 10 10 10 10 10 10 10 10 10 10 10 10 
10 Talc 2 2 2 2 2 2 2 2 2 2 2 2 
11 Magnesium stearate 2 2 2 2 2 2 2 2 2 2 2 2 
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TABLE 3 -EVALUATION OF MIXED POWDER BLEND OF LAFUTIDINE 
Formulation 
Code
Angle of repose 
(°) ± SD*
Bulk density 
(g/ml) ± SD*
Tapped density  
(g/ml) ± SD*
Carrs index 
(%) ± SD*
Hausner’s ratio 
± SD*
Drug Content 
(%) ± SD* 
F1 28.1 ± 0.09 0.704 ± 0.07 0.775 ± 0.19 19.0 ±0.01 1.10 ± 0.02 0.775 ± 0.19 
F2 26.3 ± 0.12 0.684 ± 0.18 0.833 ± 0.31 17.9 ± 0.08 1.21 ± 0.03 0.833 ± 0.31 
F3 27.34 ± 0.24 0.693 ± 0.65 0.806 ± 0.23 16.9 ± 0.03 1.16 ± 0.01 0.806 ± 0.23 
F4 26.9 ± 0.10 0.687 ± 0.35 0.840 ± 0.24 18.17± 0.01 1.22  ± 0.03 0.840 ± 0.24 
F5 30.0 ± 0.02 0.707 ± 0.17 0.848 ± 0.09 16.66 ± 0.54 1.20  ± 0.03 0.848 ± 0.09 
F6 28.0 ± 0.03 0.685 ± 0.20 0.824 ± 0.28 21.5 ± 0.02 1.20 ± 0.01 0.824 ± 0.28 
F7 24.05 ± 0.39 0.711 ± 0.12 0.790 ± 0.19 20.8 ± 0.02 1.11  ± 0.02 0.790 ± 0.19 
F8 27.37 ± 0.24 0.70 ± 0.16 0.875 ± 0.41 23.1 ± 0.0.01 1.25 ± 0.01 0.875 ± 0.41 
F9 25.75 ± 0.12 0.697 ± 0.35 0.776 ± 0.29 23.7 ± 0.01 1.11  ±  0.00 0.776 ± 0.29 
F10 29.40 ± 0.41 0.70 ± 0.16 0.875 ± 0.41 22.8 ± 0.01 1.25  ±  0.02 0.875 ± 0.41 
F11 28.61 ± 0.10 0.687 ± 0.35 0.840 ± 0.24 18.7 ± 0.02 1.22  ±  0.03 0.840 ± 0.24 
F12 27.34 ± 0.29 0.693 ± 0.65 0.806 ± 0.23 16.9 ± 0.03 1.16  ± 0.01 0.806 ± 0.23 
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TABLE 4 - EVALUATION OF ORODISPERSIBLE TABLE OF LAFUTIDINE 
Formulation 
Code 
 General 
appearance  
Thickness  
mm 
Hardness 
kg/m2 
Average weight 
(mg)  ± 7.5  
Friability 
(%) 
Content 
uniformity 
Disintegration 
Time (sec) 
Water 
absorption 
ratio (%) 
Wetting 
time (sec) 
F1 white 3.56  ± 0.01 3.26 ±0.15 200.0 ± 0.41 0.55 ± 0.51 99.55 ± 0.86 65.0 ±1.63 75.18 ± 0.50 68.17 ± 0.27 
F2 white 3.43± 0.01 3.43 ± 0.05 200.7 ±0.62 0.48 ±0.06 97.15 ±0.95 50.6 ± 0.47 71.28 ± 1.69 62.0 ±0.81 
F3 white 3.42 ± 0.01 3.16 ±0.40 199.56 ± 0.49 0.55 ±0.02 89.06 ±0.75 30.0 ± 1.63 75.18 ± 1.29 69.6 ± 1.2 
F4 white 3.32 ±0.11 3.50 ±0.40 199.2 ± 0.18 0.65 ±0.03 87.14 ±0.95 70.6 ± 2.3 60.58 ± 1.11 72.6 ± 1.2 
F5 white 3.39±0.05 3.50 ±0.40 204.6 ±0.52 0.53 ±0.16 85.78 ±0.78  45.3 ± 1.70 78.53 ± 0.84 73.0 ± 0.8 
F6 white 3.32 ±0.00 3.00 ±0.40 201.3 ± 0.63 0.60 ± 0.08 88.62 ±0.40 32.3 ±1.70 85.72 ± 0.43 70.9 ± 0.55 
F7 white 3.42 ±0.00 3.66 ±0.84 202.6 ±0.58 0.57 ± 0.16  90.24 ±0.31 50.0 ± 1.63 71.53 ± 0.43 56.0 ± 1.6 
F8 white 3.32 ±0.00 3.33 ±0.23 199.1 ±0.53 0.59 ±0.14 88.71 ± 0.31 40.0 ± 1.33 71.53 ± 1.07 65.9 ± 0.4 
F9 white 3.39 ±0.00 3.66 ± 0.84 193.4 ±0.37 0.59 ± 0.01 88.94 ±0.85 25.0 ± 1.47 96.64 ± 1.89 54.0±1.6 
F10 white 3.32 ±0.00 3.66 ± 0.84 198.2 ± 0.19 0.52 ±0.01 99.98 ±0.72 25.6 ± 0.21 81.65 ± 1.78 56.0 ±1.4 
F11 white 3.43 ± 0.17 3.76 ± 0.40 199.0 ±0.08 0.53 ±0.068 99.17 ± 0.06 20.6 ± 0.96 94.11 ± 1.89 61.2 ± 0.23 
F12 white 3.43 ± 0.05 3.16 ± 0.62 199.2 ± 0.48 0.55 ±0.02 99.94 ± 0.06 18.0 ± 0.4 98.78 ± 1.89 69.1 ± 1.2 
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Table 5 A - VITRO RELEASE PROFILE OF LUFUTIDINE ORODISPERSIBLE TABLETS 
Time in 
Minutes 
Cumulative Percentage drug release ± SD* 
 F1 F2 F3 F4 F5 F6 
5 41.75 ± 0.29 30.43 ± 0.86 32.35 ± 0.87 33.40 ± 0.29 26.42 ± 0.32 17.68 ± 1.04 
10 54.45 ± 0.22 48.66 ± 1.49 59.58 ± 1.49 58.70 ± 0.18 37.85 ± 0.42 32.78 ± 0.45 
15 62.49 ± 0.96 60.76 ± 2.16 65.28 ± 2.47 67.13 ± 0.41 50.58 ± 0.51 53.47 ± 1.13 
20 79.35 ± 2.77 76.84 ± 2.72 76.76 ± 3.32 78.49 ± 0.29 67.44 ± 1.81 64.89 ± 1.19 
25 77.39 ± 2.09 83.66 ± 1.53 85.62 ± 2.76 87.21 ± 0.44 72.84 ± 0.41 72.84 ± 0.41 
30 87.13 ± 1.05 86.51 ± 0.52 94.44 ± 1.82 94.05 ± 0.47 90.20 ± 1.50 86.20 ± 1.50 
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Table  5 B - VITRO RELEASE PROFILE OF LUFUTIDINE ORODISPERSIBLE TABLETS 
Time in Minutes Cumulative Percentage drug release ± SD* 
F7 F8 F9 F10 F11 F12 
5 17.90 ± 1.04 33.40 ± 0.29 12.93 ± 0.23 31.65 ± 0.20 33.40  ± 40 59.22 ± 1.19 
10 25.82 ± 0.45 58.70 ± 0.18 26.43 ± 0.54 51.42 ± 0.46 58.70 ± 0.18 80.31 ± 1.18 
15 33.24 ± 1.13 67.13 ± 0.41 40.61 ± 0.94 65.89 ± 1.19 67.13 ± 0.41 89.67 ± 0.34 
20 43.89 ± 1.19 78.49 ± 0.29 55.54 ± 1.47 76.21 ± 1.50 78.49 ±0.29 91.12 ± 0.33 
25 58.70 ± 0.41 87.21 ± 0.44 71.42 ± 4.61 83.21 ± 1.42 87.49 ± 0.44 95.49 ±1.41 
30 88.87 ± 1.50 94.05 ± 0.47 88.55 ± 1.19 92.38 ± 0.45 94.05 ± 0.47 97.79 ± 0.88 
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Figure  6   λ OF LAFUTIDINE 
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Figure  7 CALIBRATION OF LAFUTIDINE IN PHOSPHATE BUFFER        
pH 6.8 
Figure 8  FT-IR STUDIES OF LAFUTIDINE 
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Figure  9  FT-IR STUDIES OF CROSPOVIDONE 
Figure 10 FT-IR STUDIES OF DRUG +CP 
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Figure 11  FT-IR STUDIES OF SCMC 
Figure 12 FT-IR STUDIES OF  DRUG + SCMC 
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Figure 13  FT-IR STUDIES OF  PRE STARCH 
 
Figure 14  FT-IR STUDIES OF  LAFUTIDINE + SCMC +PRE GELATNIZED 
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Figure 15  DSC THERMOGRAM OF LAFUTIDINE  
Figure  16 BEST FORMULATION OF LAFUTIDINE  
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Figure 17 FORMULATION AND EVALUATION OF MIXED POWDER 
BLEND 
 
Figure  18 
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Figure  19
Figure  20
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Figure  21
Figure  22
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Figure  23 
 
Figure 24 
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Figure  25
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Figure  27 
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Figure  29 
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Figure  30
Figure 31
CHAPTER 10                  TABLES  AND FIGURES  
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 117 
Figure 32
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CHAPTER-X 
SUMMARY AND CONCLUSION 
• The purpose of the study was to formulate and evaluvate oral dispersible
tablets of Lafutidine. The results of the fourier. Transmission Infra -red
spectroscopy confirm that both drug and excipients are compatible with
each other and are devoid of intraction.
• The DSC thermogram of formulation the sharp endothermic peak of pure
drug appeared at 99.690C which reveals that there was no interaction
between drug and physical mixture.
• The results of pre compression studies like angle of repose,bulk
density,tappe density,compressibility index and hausnerss ratio reveals
that the prepared powder blends of all formulations were possess good
floe properties.
• F1,F2,F3 formulations are prepared by using sodium carboxy methyl
cellulose in 2%,3%,4% respectively.F4,F5,F6 formulations prepared by
using cros povidne super disintegrants  in 2%,3%,4%
respectively.F7,F8,F9 formulation prepared by using pre gelatinized
starch super disintegrants in 2%,3%,4% respectively. F10,F11,F12
formulation prepared by using combination of sodium carboxy methyl
cellulose,cros povidone,pregelatinized starch in 3%,4.5%,12%
respectively.
• The prepared tablets were subjected to post compression evaluvations
and the results indicate that the hardness,thickness and diameter of all
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the tablets are uniform,which ensure that all the tablets were of uniform 
size and shape with good resistants against mechanical damage.The 
tablets of all formulation contains uniform amount of drug,which ensures 
content uniformity of tablet formulations. 
• The prepared tablets were within the limits of weight variation test,which
in turn indicate uniform distribution of contents of the powder blends of
each formulation. The friability of all the tablets was found to be <1%
which indicates the good mechanical resistance.
• The tablets of all formulation were found to have minimum wetting time
and maximum water absorption ratio which is the desired charecterstic
of oral dissolving tablets which enables faster disintegration of tablets.
The disintegration time of all tablets were found to be less than 3 minutes
,which ensures faster disintegration except formulation(F1 & F2)
CHAPTER  XI                 SUMMARY AND CONCLUSION 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 120 
CONCLUSION
 Oro dispersible tablets is a promising approach with a view of obtaining 
faster action of drug and would be advantageous in com parison to currently 
available conventional forms.  In this study or dispersible tablets of lafutidine 
were prepared by direct compression method using crosspovidone, sodium 
carboxy methyl cellulose and pregelatinized were used in formulation.   
Formulation F12 containning 4.5% crospovidone has shown the better 
results for disintegration time of 18 seconds. In-vitro dissolution study showed 
97.79% of drug release at the end of 30 minutes. From the study, it can be 
conclude that the oro- dispersible tablet of lafutidine could perform better 
bioavailability, effectiveness and hence better patient compliance. 
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